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ABSTRACT 
The underlying mechanisms in the asthmatic airway inflammation involve the 
interaction between different cells and mediators that consequently result in different 
clinical phenotypes. The aim of this thesis was to investigate the impact of 
inflammatory mediators, with emphasis on eicosanoids, on the inflammatory and 
functional airway responses under basal and triggered conditions in subjects with 
asthma, in particular ASA/NSAID-intolerant and allergic phenotypes. In the studies 
included in this thesis, we investigated the possibility of finding new phenotype-
specific biomarkers of asthma in connection with mechanistic pathways of eicosanoid 
biosynthesis. The studies were possible because of careful and extensive 
characterizations of the patients. 
Eleven aspirin-sensitive asthmatics had, in comparison with ten aspirin-tolerant 
asthmatics, higher exhaled nitric oxide levels and higher baseline levels of CysLTs in 
saliva, sputum, blood ex vivo and urine. Levels of urinary LTE4 and 9α,11β-
prostaglandin F2 increased after aspirin provocation whereas leukotriene levels in saliva 
and ex vivo stimulated blood did not increase. These findings support a selective 
CysLT-overproduction in this distinct clinical syndrome. CysLTs in saliva should be 
explored as a new and clinically convenient biomarker of AIA and other diseases 
associated with increased production of leukotrienes. 
In an explorative study, the capacity of eosinophils to produce 15-LO pathway 
products and their ex vivo responsiveness to COX inhibition was studied in the 
peripheral blood drawn from healthy volunteers and three asthma groups. In the 
absence or presence of lysine-aspirin, eosinophils were stimulated with arachidonic 
acid and calcium ionophore to trigger the 15-lipoxygenase-1 (15-LO) and 5-
lipoxygenase (5-LO) pathways, respectively. The results displayed an increased release 
of the recently discovered lipid mediator eoxin C4 (EXC4) as well as the main indicator 
of 15-LO activity, 15-HETE, in activated eosinophils from severe and aspirin-intolerant 
asthmatics. Eosinophils from AIA subjects also showed elevated EXC4 and LTC4 
formation after cellular activation in the presence of lysine-aspirin.  This higher 
biosynthetic activity of 15-LO pathway in AIA is in part due to increased numbers of 
eosinophils, but the data also support enhanced eosinophil function, possibly involving 
transcellular interactions with platelets. The findings support contribution of 15-LO 
pathway in the pathophysiology of severe and aspirin-intolerant asthma.   
This thesis also aimed at evaluating the role of COX-1 and COX-2 in the 
biosynthesis of the pro-inflammatory prostaglandin D2 (PGD2) and bronchoprotective 
prostaglandin E2 (PGE2) under basal conditions and during heightened airway 
inflammation and responses after inhaled allergen provocation. Eighteen subjects with 
asthma and six healthy controls participated in a cross-over study where a selective 
COX-2 inhhibitor, celecoxib 200 mg, or placebo were given b.i.d. on 3 consecutive 
days following 2 untreated baseline days. 
 Celecoxib treatment inhibited urinary excretion of the tetranor metabolite of 
PGE2, PGEM, by 50% or more in asthmatic subjects and healthy controls, whereas 
there was no significant change in the excretion of the tetranor metabolite of PGD2, 
PGDM. In addition, celecoxib did not cause any significant changes in FEV1 or FENO. 
In comparison with the healthy controls, the subjects with asthma had higher baseline 
levels of urinary PGDM but not of PGEM. These findings indicate that biosynthesis of 
  
PGD2 is catalysed predominantly by COX-1 and that COX-2 contributes substantially 
to the biosynthesis of PGE2. The asymmetric impact of COX-2 inhibition on prostanoid 
formation raises the possibility of long-term adverse consequences of COX-2 inhibition 
on airway homeostasis by the decreased formation of PGE2 and maintained production 
of increased levels of PGD2 in asthmatics.  
Therefore, the effect of selective COX-2 inhibition on induced asthmatic airway 
obstruction and inflammation was investigated in 16 subjects with mild atopic asthma 
who underwent rising dose inhalation challenges with allergen and methacholine 
(MCh) to determine the provocative dose causing a 20% drop in FEV1 (PD20) during a 
control study period and following 10-13 days of treatment with etoricoxib (90 mg 
once daily). Study periods were randomized with at least 2 weeks washout between and 
induced sputum cells and exhaled nitric oxide levels (FENO) were used to assess airway 
inflammation. Blood assays for COX-1 and COX-2 activity to determine biochemical 
efficacy were performed and urinary excretion of lipid mediators was measured by 
mass-spectrometry. The intervention with COX-2 inhibitor in provoked asthma was not 
found to have any negative effects on allergen-induced airflow obstruction and sputum 
eosinophils, basal lung function or methacholine responsiveness. The study suggests 
that short-term use of COX-2 inhibitors is safe in asthmatics. 
In summary: 1) The higher baseline LTE4 levels found in three body matrices 
lends further support to CysLT-overproduction in AIA and the higher salivary levels 
should be explored as a new and clinically convenient biomarker of AIA and other 
diseases with increased CysLT-production. 2) The increased release of the 15-LO 
products, EXC4, and 15-HETE, in activated eosinophils from severe asthma and AIA 
patients, and the elevated EXC4 and LTC4 formation in activated eosinophils from AIA 
subjects in the presence of ASA support a pathophysiological role of the 15-LO 
pathway in AIA and severe asthma. 3) Basal biosynthesis of PGD2 is increased in 
subjects with asthma and its formation is catalysed predominantly by COX-1. By 
contrast, COX-2 contributes substantially to the biosynthesis of PGE2. 4) COX-2 
inhibition in provoked asthma is found to have no negative effects on allergen-induced 
airflow obstruction and sputum eosinophils, basal lung function or MCh responsiveness 
suggesting that short-term use of COX-2 inhibitors is safe in asthmatics. 
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POPULÄRVETENSKAPLING SAMMANFATTNING 
 
Astma kännetecknas av inflammation i luftrören och leder till luftvägsbesvär i 
form av hosta, ökad slemproduktion och varierande grad av andnöd. 
Luftvägsinflammationen karakteriseras av inblandning av celler såsom 
eosinofiler, mastceller och neutrofiler samt en rad inflammationsförmedlande 
produkter. I huvudsak finns två typer av astma; allergisk och icke allergisk 
astma. Astma kan utlösas eller försämras av en eller flera faktorer, t ex vid 
exponering för allergener, kall luft, fysisk ansträngning, luftburna kemiska 
ämnen och läkemedel. 
 Det dominerande inflammationsmönstret kan eventuellt förklara de olika 
typer och svårighetsgrader av astma. En special typ av astma är den aspirin-
intoleranta där patienterna får luftvägsbesvär som oftast är av svårare art och 
ibland livshotande när de tar värktabletter som innehåller aspirin eller andra 
smärtstillande och inflammationsdämpande läkemedel med samma 
verkningsmekanism. För att med säkerhet ställa diagnosen ASA/NSAID-
intolerant astma (AIA) krävs provokation med acetylsalicylsyra (ASA) som är 
tidskrävande och görs på specialist-kliniker med erfarenhet inom fältet. Det är 
en fördel att inom det kliniska arbetet hitta specifika inflammationsmarkörer. 
Detta gör det möjligt att särskilja de olika typerna och erbjuda de mest 
effektiva terapeutiska möjligheterna. Sådana biomarkörer har dock inte 
kommit till bredare vardagligt kliniskt arbete.  
I denna avhandling har den astmatiska inflammationen och de funktionella 
luftvägssvaren studerats, under basala förhållanden och vid kontrollerade 
astmaattacker utlösta vid det kliniska laboratoriet. Avhandlingen är 
koncentrerad på att utreda betydelsen av nyckelmolekyler inom 
arakidonsyrafamiljen, dvs prostaglandiner (PG), leukotriener (LT) och härmed 
besläktade föreningar. Vi har studerat patienter med olika typer och 
svårighetgrader av astma, i synnerhet aspirin-intoleranta och allergiska 
astmatiker. 
I delarbete I, genomfördes en jämförelse mellan aspirin-toleranta och 
intoleranta avseende CysLT- och leukotrien (LT)B4-nivåer i saliv, sputum och 
ex vivo stimulerat blod under basala och triggade förhållanden efter bronkial 
provokation med ASA. Inducerat sputum, saliv, blod och urin samlades från 
21 astma patienter. Elva av dessa patienter visade sig ha AIA som verifierades 
under studien med en positiv inhalerad ASA-provokation och de resterande tio 
patienter var ASA-toleranta. Urin undersöktes för CysLT, LTB4 och PGD2-
metaboliten 9α,11β-PGF2. Utandat kväveoxid mättes i utandningsluften. 
Resultat: I jämförelse med ASA-toleranta astmatiker, hade AIA patienter 
högre värden av utandat kväveoxid och högre nivåer av CysLT i saliv, sputum 
och ex vivo stimulerat blod. LTB4-nivåerna mellan de båda astma-typerna 
visade dock ingen skillnad. Medan LTE4 och 9α,11β-PGF2 i urin ökade efter 
ASA provokationen, visade dessa lipidmarkörer ingen signifikant ökning i 
saliv eller ex vivo stimulerat blod. 
Diskussion: Den högre basala LTE4 hos aspirin-känsliga astmatiker i 
inducerat sputum, saliv och ex vivo stimulerat blod stödjer den ökade CysLT-
produktionen vid AIA och att den högre basala LTE4-nivån i saliv kan vara en 
kliniskt användbar markör för AIA och andra sjukdomar med CysLT-
  
överproduktion. 
I delarbete II, genomfördes en explorativ studie för att undersöka om en typ 
av vita blodkroppar, eosinofilerna, via enzymet 15-LO, har kapaciteten att 
bilda bioaktiva lipider som kan användas som biomarkörer för AIA. Trots den 
karakteristiska eosinofilin vid AIA, har man inte studerat hur ASA, i 
eosinofiler, påverkar syntesen av arakidonsyra metabloiter via 5- och 15-LO. 
Perifert blod togs från friska personer och tre astma-grupper med lindrig, svår 
och aspirin-intoleranta astma. Med eller utan aspirin, stimulerades de isolerade 
eosinofilerna med arakidonsyra och calcium ionophore för att trigga 15-
lipoxygens respektive 5-lipoxygenas. 15-HETE och eoxiner mättes som 15-
LO produkter och LTC4 som 5-LO-produkt. 
Resultat: Aktiverade eosinofiler från aspirin-intoleranta och patienter med 
svår astma producerade fem gånger så hög nivå av 15-HETE som friska och 
patienter med lindrig astma. Eosinofiler isolerade från samtliga astmagrupper 
genererade högre nivå av 15-HETE vid inkubation med ASA. Eosinofiler från 
aspirin-känsliga astmatiker, i närvaro av ASA, producerade signifikant högre 
nivåer eoxin (EX) C4 och LTC4. Under samma förhållanden genererade 
eosinofiler från aspirin-känsliga och patienter med svår astma högre nivåer av 
LTC4 and 15-HETE. 
Diskussion: Aktiverade eosinofiler från patienter med AIA har kapaciteten att 
bilda EXC4 och produktionen ökar när eosinofilerna stimuleras i närvaro av 
ASA. Den observerade högre produktionen av 15-HETE i eosinofiler isolerade 
från patienter med AIA är i linje med tidigare studier. Den ökade 15-LO-
aktiviteten kan bero på ett större antal eosinofiler hos patienter med AIA men 
kan också bero på ökad eosinofil-funktion som möjligen förklaras av en 
transcellulär interaktion med blodplättarna. Fynden i denna studie stödjer en 
roll av 15-LO i luftvägsinflammationen vid aspirin-intolerant och svår astma  
I delarbete III, undersöktes rollen som cycloxygenas (COX)-1 och COX-2 
spelar i biosyntesen av prostaglandin(PG) D2 och PGE2 under basala 
förhållanden. Aderton patienter med astma och sex friska personer deltog i en 
”cross-over” studie. En selektiv COX-2 hämmare, celecoxib 200 mg, eller 
placebo gavs två gånger dagligen under tre sammanhängande dagar. 
Lungfunktion och utandat kväveoxid mättes och urin samlades för eicosanoid-
metaboliter såväl basalt som under behandlingsperioden. 
Resultat: Celecoxib hämmade utsöndring av tetronor PGE2-metaboliten, 
PGEM, med 50% eller mer hos astma patienterna och de friska personerna. 
Däremot visade tetranor PGD2-metaboliten, PGDM, i urin ingen signifikant 
ändring. I jämförelse med de friska personerna, hade astmatikerna basalt högre 
PGDM i urin. Ingen signifikant ändring kunde ses i lungfunktionen eller 
utandat kväveoxid-värdena efter behandling med celecoxib.   
Diskussion: Patienter med astma demonstrerade ökad basal biosyntes av 
PGD2 som katalyseras huvudsakligen av COX-1. Däremot bidrar COX-2 
väsentligen till biosyntesen av PGE2. Den kraftiga hämningen av biosyntesen 
av det bronkprotektiva PGE2 och den bibehållna höga basala produktionen av 
det pro-inflammatoriska PGD2 kan öka möjligheten för negativa långsiktiga 
konsekvenser på luftvägarna av selektiv COX-2 hämning. 
I delarbete IV, deltog 16 patienter med lindrig atopisk astma i en ”cross-over” 
studie (en behandlad och en obehandlad period) för att undersöka effekten av 
  
selektiv COX-2 hämning på allergen-inducerad bronkkonstriktion. Patienterna 
genomgick inhalationsprovokationer med allergen och metakolin i början och 
i slutet av behandlingsperioden. Den provokativa dosen som orsakar en 
sänkning av FEV1 med 20% följdes under den behandlade perioden 
(etoricoxib 90 mg en gång dagligen under 10-13 dagar) och under den 
obehandlade perioden. Studie-perioderna var randomiserade och separerade 
med minst två veckor (washout). Antalet celler i inducerat sputum och utandat 
kväveoxid användes som luftvägsinflammations-markörer. Blod togs för 
mätning av COX-1 och COX-2 aktivitet. Urin samlades för mätning av 
eicosanoid-metaboliter. 
Resultat: Etoricoxib orsakade inga signifikanta förändringar i den basala 
lungfunktionen, allergen- eller metakolin-luftvägssvaret. Den allergen-
inducerade ökningen i antalet sputum-eosinofiler visade ingen signifikant 
skillnad mellan de behandlade och obehandlade perioderna. Utandat 
kväveoxid visade heller ingen skillnad mellan perioderna. Biokemiska 
blodprover och den hämmande effekten på utsöndring av tetranor PGE2 i urin 
bekräftade den selektiva COX-2 hämningen. 
Diskussion: Denna första studie av COX-2 hämning hos allergen-provocerade 
patienter med lindring atopisk astma visade inga negativa effekter av 
etoricoxib på allergen-inducerad luftvägsobstruktion, sputum-eosinofiler, basal 
lungfunktion eller metakolin-luftvägssvaret. Fynden i denna studie talar för att 
korttidsbehandling med COX-2 hämmare kan vara säker hos patienter med 
lindrig atopisk astma. 
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1. Background 
 
1.1 Asthma – A considerable burden  
Asthma is one of the most common chronic disorders affecting both children and adults 
with a prevalence varying widely around the world probably due to gene-by-
environment interactions. The increase in asthma among children and adolescents has 
recently leveled off in several westernized countries(1-3). However, diverging and 
opposite trends in Germany and United Kingdom have been pointed out(3-5).  
In Sweden, asthma is still highly prevalent with a current prevalence between 8-
10%(6). In a more recent study, the prevalence of obstructive airway symptoms 
common in asthma did not increase in Swedish young adults from 1990 to 2008 
suggesting the previous upward trend in asthma has recently reached a plateau(7). 
Asthma burdens the healthcare system and the society every year because of its 
considerable contribution to lowered quality of life and lost productivity(6-8). 
 
1.2 Definition of asthma 
The Global Strategy for Asthma Management and Prevention developed by GINA, 
Global Initiative of asthma, defines asthma, based on its clinical, physiological and 
pathological characteristics, as recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or in the early morning. Wide-spread, but 
variable airflow obstruction within the lungs is associated with these episodes which 
are often reversible spontaneously or with treatment. Many cells and cellular elements 
play a role in this chronic inflammatory disorder and the associated airway 
hyperresponsiveness(8). 
 
1.3 Asthmatic Inflammation 
The airway inflammation in asthma, which is associated with an exaggerated 
contractile response of the airways to a variety of stimuli, reflects a distortion of the 
balance normally found between immune cells, the epithelium and the host immune 
response. Asthma appears to presume both exposure to appropriate stimuli and a 
genetic predisposition.  
There is substantial evidence that human mast cells (MC) contribute to the 
pathophysiology of asthma via formation and release of an array of pro-inflammatory 
mediators and cytokines. The mast cells exhibit a tailored pathogen- and antigen-
specific immune responses, i.e. the pattern of this MC contribution varies depending on 
the stimulus(9). Mast cells in normal human lungs are usually found in close 
association with blood vessels in the lamina propria. In asthmatic subjects, mast cells 
are observed in the airway epithelium(10), mucous glands, and the airway smooth 
muscle(11-13).  
Mast cell precursors, derived from hematopoietic stem cells, migrate to the 
peripheral tissues, complete their differentiation and maturation and take up 
residence(14). When activated by specific antigens and IgE through FcεRI or by other 
endogenous or exogenous substances or stimuli, mast cells rapidly generate and release 
newly formed eicosanoids which can initiate, heighten or dampen inflammatory 
responses and cause broncho-constriction(10,15-17). 
 2 
Multiple lines of evidence suggest an important immunoregulatory role of 
eosinophils in asthma. Eosinophil counts in the blood and eosinophilic infiltration of 
the lungs have long been correlated with asthma severity(18). Interleukin (IL)-5 is 
known to have a central role in eosinophil differentiation and survival(19). Recent 
studies of eosinophil depletion with anti-IL-5 therapy have shown clinical improvement 
in subjects with refractory asthma whose selection for the treatment was based on 
finding of eosinophils in sputum. Eosinophils have the capacity of elaborating lipid 
mediators derived from arachidonic acid via both 5- and 15-LO pathways. In 
eosinophils, LTC4 synthase catalyzes the biosynthesis of LTC4 from LTA4 (20); 
alternatively, 15-HETE and eoxins are formed via 15-LO. Eosinophils also produce 
oxygen radicals, numerous cytokines e.g., IL-4, IL-5 IL-13 and TNF-α as well as 
chemokines(21). In addition to mast cells and eosinophils, the inflammatory process in 
asthma involves other cells like neutrophils and CD4+T lymphocytes.  
Neuronal mechanisms contribute also to the pathogenesis of asthma. In addition 
to control of airway smooth muscle tone and gland secretion, evidence has mounted for 
a bidirectional interaction between inflammatory cells and airway innervation; the 
neuronal chemotactic activity in the lungs leads to recruitment of inflammatory cells 
which in turn results in release of neurotransmitters that affect not only contractility of 
airway smooth muscles, but also inflammatory responses(22-25). 
In my research studies, the focus has been put on investigating the role of 
different lipid mediators, eicosanoids, on the asthmatic airway responses and the 
associated inflammation.  
 
1.4 Asthma phenotypes 
Different phenotypes of asthma have been recognized since many years with the focus 
initially put on the clinical and physiological characteristics. However, the 
heterogeneity/complexity of asthma requires a more precise identification of the 
phenotypes with the necessity to link biomarkers to phenotype(26). 
In this thesis, allergic and ASA/NSAID-intolerant asthma (AIA) were studied, as 
eosinophils and mast cells with their inflammatory mediators are known to be involved 
in the pathogenesis of these two asthmatic phenotypes. The study of the role of lipid 
mediators released by these cells, as possible determinants of phenotypic differences, 
may lead to the unraveling of novel characteristic biomarkers. 
 
1.4.1 ASA/NSAID-intolerant asthma 
ASA/NSAID-intolerant asthma (AIA) is a distinct clinical syndrome characterised by 
chronic non-allergic asthma associated with chronic hyperplastic rhinosinusitis that is 
acutely precipitated/exacerbated by ingestion of ASA and related non-steroidal anti-
inflammatory drugs (NSAIDs)(27). A few years after that aspirin was marketed by 
Bayer 1898, serious respiratory symptoms attributed to this substance were 
reported(28). In 1922, Widal documented the association of ASA sensitivity, asthma 
and nasal polyposis, and further, the first ASA challenges and desensitization were 
pioneered(29). This clear-cut syndrome runs an intractable course of inflammation in 
both upper and lower respiratory tract with an average age of onset around the third 
decade of life and with women being more affected than men(30,31). In 1968, Samter 
and Beers described a syndrome consisting of asthma, aspirin sensitivity, and nasal 
polyps, which came to be known as Samter's triad(32).  
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Components of AIA usually develop over a period of years(31,33). The majority 
of patients initially develop refractory rhinitis (often following viral infection) usually 
established by early thirties. This is followed by the development of chronic 
hypertrophic eosinophilic rhinosinusitis, characterized by anosmia and nasal polyposis. 
The reaction is not an allergy, but is triggered by the pharmacological effect of 
cyclooxygenease-1 (COX-1) inhibitors, whereas specific COX-2 inhibitors, so called 
coxibs, are generally tolerated by subjects with this asthma phenotype(34,35). The 
number of eosinophils in the blood and bronchial mucosa of subjects with AIA is 
higher in comparison with ASA-tolerant asthmatics(36,37). AIA is also characterized 
by overproduction of cysteinyl leukotrienes (CysLTs) at baseline and further elevation 
occurs after exposure to aspirin(38). 
Estimates of the prevalence of ASA/NSAID-intolerant asthma reported from 
different parts of the world exhibit a considerable variation depending on whether the 
diagnosis is based on medical history alone or in combination with ASA challenge 
tests(39). To date, there is no in vitro diagnostic test for this asthmatic phenotype which 
is often severe and sometimes even life-threatening. A higher number of asthmatics 
may suffer from this intolerance reaction urging the necessity of improved diagnostic 
measures. Conversely, many subjects with asthma are unnecessarily warned against 
taking ASA and NSAIDs which are important therapeutics in treating pain and 
inflammatory diseases and as a prophylactic measure in cardiovascular diseases. 
 
1.4.2 Allergic asthma 
Approximately 50% of all adult asthmatics have allergic asthma which frequently 
coexist with allergic rhinitis(40,41). Allergic asthma is primarily an airway 
inflammation associated with involvement of T helper type 2 (TH2) cells that promote 
IgE production and recruitment of mast cells and eosinophils. TH2-type cytokines 
orchestrate the inflammatory cascade in allergic asthma, including TH2 cell survival  
(regulated by IL-4), B cell isotype switching to IgE synthesis  (IL-4 and IL-13), mast-
cell differentiation and maturation  (IL-3, IL-9 and IL-13), eosinophil maturation and 
survival  (IL-3, IL-5 and GM-CSF) and basophil recruitment  (IL-3 and GM-CSF).  
The allergic airway inflammation involves allergen-specific immunoglobulins 
(Ig)E, that bind to high-affinity Fcε receptors on the surfaces of basophils and mast 
cells present in the subepithelial layer of the airways leading to release of inflammatory 
mediators such as leukotrienes, prostaglandins, and histamine that possess the capacity 
to cause contraction of airway smooth muscle cells and induce edema and mucus 
secretion(42). 
Sensitized subjects that inhale a relevant allergen develop airway constriction 
usually within 10 minutes of exposure.  This early appearing reaction, the early 
asthmatic reaction (EAR), reaches a maximum within 30 minutes and resolves in 
general within 1-3 hours.  In some subjects, the airway obstruction may persist or recur 
after 3-4 hours, developing into the late asthmatic reaction (LAR), to reach a maximum 
within 8-12 hours and lasting up to 24 hours or more(43). 
 
1.5 Eicosanoids 
Eicosanoids are diverse lipid mediators of inflammation derived from the cell 
membrane bound polyunsaturated fatty acid precursor arachidonic acid and consist of 
prostanoids (prostaglandins, thromboxane and prostacyclin), leukotrienes, lipoxins and 
a number of additional metabolites (figure 1). These biologically active lipids serve 
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regulatory and homeostatic functions in inflammation and have several roles in the 
pathogenesis of asthma. In response to various inflammatory stimuli, the complex 
interplay of eicosanoids can differently influence the nature, intensity and duration of 
airway responses in asthma(44,45). 
 
 
 
 
 
 
In 1971, Vane demonstrated that the pharmacological actions of aspirin and 
related drugs were due to the inhibition of biosynthesis of prostaglandins(46). A few 
years later, Szczeklik and colleagues proposed a non-allergic mechanism underlying 
precipitation of asthmatic exacerbation by compounds sharing aspirin-like activity that 
inhibited cyclooxygenase enzyme in sensitive patients(47,48). In the COX pathway, 
arachidonic acid (AA) in cell membranes serves as a precursor for prostanoids(49).  
Cyclooygenase enzyme exists at least as two isoforms, COX-1 and COX-2(50). 
COX-1 is constitutively expressed in most tissues and is responsible for the basal 
production of prostanoids involved in “housekeeping” functions, whereas COX-2 is 
undetectable in most tissues, but highly inducible and can be up-regulated during 
inflammatory conditions(51-53). 
Aspirin and related NSAIDs show different potencies in inhibiting the respective 
isoenzymes(54) and a positive correlation has been found between in vitro potency 
prostaglandin biosynthesis inhibition by a drug and its risk for precipitating aspirin-
induced asthma symptoms(47). Thus, aspirin and NSAIDs like indomethacin and 
piroxicam that are more potent inhibitors of COX-1 than COX-2 isoenzyme, always 
precipitate asthma attacks in AIA patients.  
Contrary to nonselective NSAIDs, drugs preferentially inhibiting COX-2, such as 
nimesulide and meloxicam, are usually well tolerated by AIA patients at therapeutic 
doses in these patients(35,55-57). Furthermore, there is a strong body of evidence that 
highly selective COX-2 inhibitors, so called coxibs, are well tolerated by patients with 
Figure 1. Schematic representation of 
eicosanoid pathways 
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ASA/NSAID-intolerant asthma(35,58-60). Selective inhibitors of COX-2 were 
introduced in 1999 and celecoxib was one of the first selective COX-2 inhibitors with a 
selectivity estimated by the human whole blood assay, in favor of COX-2, i.e. a potent 
inhibitor of COX-2 and weak inhibitor of COX-1(61). Second generation selective 
COX-2 inhibitors have now been developed with higher selectivities for COX-2, e.g. 
etoricoxib with the highest selectivity in favor of COX-2(61). 
Recent trials have shown a higher incidence of cardiovascular events, including 
myocardial infarction, in patients treated with selective COX-2 inhibitors. Biosynthesis 
of the anti-thrombotic prostacyclin is prevented by the selective COX-2 inhibition, 
while formation of the pro-thrombotic thromboxane in platelets is left unopposed(62). 
Lower potency against COX-1 and higher selectivity for COX-2 is in favor of lower 
incidence of adverse events related to stomach bleedings(63-65). Colon cancer cells 
synthesize prostaglandins derived via the COX-2 pathway, PGE2 and PGI2. PGE2 has 
been implicated in cancer cell proliferation and survival and PGI2 in protecting cancer 
cells from apoptosis. COX-2 inhibitors are reported to induce cancer cell 
apoptosis(66,67). 
In order to understand the pathophysiological effects of prostanoids in asthma, it 
is important to assess the endogenous formation of these lipid mediators synthesized 
via different pathway. In humans, metabolites of prostanoids are excreted to body 
fluids, such as plasma and urine. Analysis of the more abundant tetranor metabolites of 
prostanoids in urine by liquid chromatography-tandem mass spectrometry reflects 
modulated biosynthesis and will complement the use of pharmacological interventions 
in the further elucidation of the mechanistic pathways of these lipid mediators in 
vivo(68). 
 
1.5.1 Prostaglandin D2  
Prostaglandin (PG) D2 is the most abundant lipid mediator produced by mast cells that 
exerts its inflammatory effects through activation of three different receptors (Figure 2).  
The D Prostanoid 1 receptor  (DP1), expressed by vascular smooth muscle and platelets 
is mediating vasodilatation(69,70) and inhibition of platelet aggregation(71), and the 
chemoattractant-homologous receptor  (CRTH2), expressed preferentially by Th2 
lymphocytes, eosinophils and basophils(72,73) which mediate chemotactic responses 
of these cells to PGD2(74). In addition, PGD2 is also known to act via the receptor for 
thromboxane A2 (TXA2), the TP receptor(75). The TP receptors are expressed on 
bronchial and vascular smooth muscle cells, blood platelets and myofibroblasts(76,77) 
and are known to mediate a strong and long-lasting contraction in these tissues(78,79).  
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In general, PGD2 is thought to influence the asthmatic airway causing 
bronchoconstriction, vasodilation, increased vascular permeability and mucous 
formation(70,80-84). Howarth and colleagues investigated the effect of a potent TP 
receptor antagonist on the bronchoconstriction induced by inhaled PGD2 in atopic 
asthmatics and found only partial protection suggesting that the vascular DP receptor 
may play a more important role in PGD2-induced lower airway constriction than has 
previously been recognized(85). 
Allergen challenge has been shown to lead to rapid production of PGD2 in the 
airways of asthmatics(17) and the nasal mucosa of allergic rhinitis(86). The ASA-
induced bronchoconstriction in patients with aspirin-intolerant asthma (AIA) is 
followed by a significant dose-depenedent increase in the urinary excretion of the early 
appearing PGD2 metabolite, 9α,11β PGF2(87,88).  
Measurement of PGD2 and its metabolites in asthmatic subjects has mostly been 
performed in urine, bronchoaveloar lavage fluid, induced sputum and plasma(17,89-
91). The amounts of PGD2 produced by eosinophils, platelets, macrophages and Th2 
lymphocytes is 100-1000 times lower than those produced by activated mast cells. 
Thus, the urinary PGD2 metabolites serve as useful markers of mast cell activation(92-
94). The “F-ring” PGD2 metabolites in urine, 9α,11β-PGF2 and 2,3-dinor-9α,11β-PGF2, 
has been used in the clinical studies related to asthmatic airway inflammation(93-95). 
Recently, the most abundant “D-ring” PGD2 metabolite in urine, 11,15-dioxo-9α-
hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid  (tetranor-PGDM) was identified(68), 
(figure 3). 
 
1.5.2 Prostaglandin E2 (PGE2) 
Prostaglandin E2 plays an important role in regulating inflammatory processes and 
through four E-prostanoid  (EP) receptors, EP1, EP2, EP3, and EP4 evokes diverse 
actions in humans(96,97). In the airways, the epithelial and endothelial cells, the airway 
smooth muscle, and the monocytes/macrophages are the main sources of PGE2 
Figure 2. Prostaglandin D2 receptors and effects 
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production(98). PGE2 is generally thought to have proinflammatory properties in 
several inflammatory conditions, e.g. in rheumatoid arthritis(99). However, PGE2 in 
respiratory tract is presumed to be bronchoprotective(100-103). O'Byrne and colleagues 
demonstrated that inhaled PGE2 in asthmatic subjects markedly attenuated exercise 
bronchoconstriction which was not thought to occur through functional antagonism of 
airway smooth muscle(104). Furthermore, PGE2 has been shown to provide almost 
complete protection against aspirin-induced bronchoconstriction in subjects with 
known AIA with inhibition of the increase in urinary LTE4 following lysine-ASA 
bronchoprovocation(105). In atopic asthmatics, inhaled PGE2 before allergen challenge 
prevented the decline in airflow associated with EAR and LAR(106). Following 
inhalation of PGE2, the increase in AHR seen during LAR was attenuated as were the 
number of eosinophils recovered in sputum(103). 
 
 
 
 
 
In animals, many in vitro studies have reported airway relaxation induced by 
prostaglandin E2(107,108).  Early studies with unselective receptor antagonists 
suggested involvement of the receptor EP2 in the bronchial relaxation induced by PGE2 
in human bronchial preparations(109). Recently, PGE2-induced bronchodilation of 
human bronchial was shown to be significantly blocked by a selective EP4 receptor 
antagonist. In addition, selective EP4 receptor agonist, but not selective EP2 receptor 
agonist, resulted in relaxation of bronchial preparations pre-contracted with 
histamine(110). Reduced synthesis of PGE2 and lowered EP2 receptor expression has 
been suggested to provoke heightened airway inflammation in asthmatic subjects(111). 
In mice, PGE2-mediated airway constriction is dependent on expression of the 
EP1 and EP3 receptors(106). It is unclear which of the PGE2 receptors have constrictive 
effects on the human airways. However, there are ongoing studies investigating the role 
of TP, EP1 and EP3 receptors in this respect. The bronchodilatory benefits of inhaled 
PGE2 are associated with irritancy of the upper airway resulting in a reflex cough which 
Figure 3. COX pathway metabolites and isoprostanes 
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is suggested to be initiated by stimulation of sensory afferent nerve endings in the 
airways(103). In animal models, the PGE2-induced cough is thought to be caused 
mainly, if not solely, by activation of the EP3 receptor, e.g. EP3 receptor antagonist in 
Guinea pigs has been shown to attenuate PGE2-induced cough in vivo(112). 
 
1.5.3 Cysteinyl leukotrienes 
The studies of the metabolism of arachidonic acid performed in late 1970’s by 
Samuelsson and co-workers led to the discovery of the 5-lipoxygense (5-LO) pathway 
and biosynthesis of leukotrienes in leukocytes(113), (figure 4). Leukotrienes are potent 
lipid mediators in the pathogenesis of asthma(114). Cysteinyl leukotrienes (CysLTs), 
LTC4, LTD4 and LTE4, appear to exert their effects through at least 2 receptors, 
CysLT1 and CysLT2 receptors(115,116). In response to activation, CysLTs are 
generated by eosinophils, basophils, mast cells, macrophages, and myeloid dendritic 
cells(45). The gene that codes LTC4 synthase is located on human chromosome 5q in a 
region linked with asthma and atopy(117). CysLTs are important bronchoconstrictors 
with LTC4 being as potent as LTD4 in this regard(118).  
 
 
 
 
In AIA, bronchoconstriction following ASA challenge appears to be due to the 
overproduction of CysLT at baseline and after provocation(119). Asthmatic airways 
have been shown to be relatively more sensitive to inhaled LTE4 compared to healthy 
individuals(120), and the inhalation of LTE4 was found to increase the numbers of 
eosinophils in the airways(121). Clinical and in vitro studies have shown that CysLTs 
are implicated in increased mucous secretion, contraction of vascular smooth muscle 
and likely in extravascular leakage(122-124). While LTC4 and LTD4 are known to have 
a short half-life in the tissue, LTE4, is the most stable CysLT with the longest half-life 
in the circulation before being excreted into the bile and urine(125). In asthmatics, 
CysLTs and leukotriene (LT)B4  are both formed from LTA4 and can be measured in 
body fluids, e.g. bronchoalveolar lavage  (BAL) fluid, urine and blood. In humans with 
Figure 4. Biosynthesis of leukotrienes via 5-Lipoxygenase pathway 
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asthma, the CysLTs are increased in BAL fluid and urine after allergen and aspirin 
provocations(126,127) and urinary release has been demonstrated in association with 
airway obstruction after challenge with exercise, adenosine and mannitol. 
The leukotriene pathway can be inhibited via inhibition of the biosynthesis or 
blocking the receptors. Zafirlukast, a very potent and selective CysLT1 receptor 
antagonist (CysLTRA), administered before allergen challenge resulted in inhibition of 
the immediate and the late response by approximately 80% and 50%, respectively(128). 
A 4-week treatment with montelukast, a potent CysLTRA, resulted in a significant 
reduction in the number of sputum eosinophils(129). Furthermore, montelukast, given 
in 16-18 hours before exercise, demonstrated sustained protection against exercise 
induced bronchospasm(130). Zafirlukast when combined with the antihistamine, 
loratadine, inhibited both EAR and LAR following allergen challenge by about 75%, 
and the combination was significantly more effective than either drug alone during the 
LAR(131). Zafirlukast has also demonstrated a beneficial effect in exercise-induced 
asthma and inhibited the bronchoconstrictive response to exercise by 57%(132). A 
specific leukotriene receptor antagonist given to ASA/NSAID-intolerant asthmatics 
resulted in a significant improvement in basal lung function with an average peak 
increase in FEV1 of 18% lending support to drugs that block the action of leukotrienes 
as a therapeutic alternative in subjects with AIA(133).   
In subjects with AIA who were on regular treatment with medium to high doses 
of inhaled or oral glucocorticosteroids, addition of a leukotriene pathway inhibitor, 
zileuton, resulted in improved basal lung function, diminished nasal dysfunction with 
remarkable return of smell, less rhinorrhea and a trend for less stuffiness and higher 
nasal inspiratory. Moreover, zileuton led to a small but distinct reduction of AHR to 
histamine, inhibited aspirin-induced bronchoconstriction and inhibited urinary 
excretion of LTE4(134). These clinical trials indicate that leukotrienes are important 
mediators of persistent airway obstruction. 
 
1.5.4 Mediators of 15-lipoxygenase pathway 
Little is known about the biological functions of human 15-LO. Abundant amounts of 
15-LO-1 exist in human airway epithelial cells, eosinophils and subsets of mast cells 
and dendritic cells(135-139,139). Several studies indicate a high level expression of the 
15-LO in human airways(138,140,141) and asthmatics in particular express a higher 
number of  15-LO expressing cells that produce significantly higher amounts of 15-
HETE(142).  
As a major metabolite of arachidonic acid produced via the 15-LO pathway 
(figure 5), 15-HETE was identified by Hamberg and colleagues in lung tissue from an 
asthmatic subject(143). In a subsequent study, mono-HETEs, especially 15-HETE, 
were found to make up the bulk of arachidonic acid metabolites identified in the lungs 
of allergic asthmatics irrespective of whether the lung was challenged with specific 
allergen or calcium ionophore(144). Kumlin and colleagues also have demonstrated 
that airway epithelium appears to be the major source of 15-HETE in the human lung 
and that the significantly higher 15-HETE found in bronchi from asthmatic subjects 
would lend support to involvement of 15-HETE in asthmatic airway 
inflammation(145). Increased formation of 15-HETE is seen after inhaled allergen 
challenge in atopic subjects supporting involvement of 15-LO in the allergic airway 
inflammation(144). Furthermore, pre-inhaled 15-HETE increased the EAR 
significantly, whereas the LAR was not influenced(146). However, conflicting results 
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in this context, with both lack of effects and increased airway responses have been 
reported(135).  
 
 
 
 
 
Eoxins (EX), EXC4, EXD4, and EXE4, are pro-inflammatory mediators also 
formed via 15-LO-1 pathway in human eosinophils and mast cells(147). Eosinophils 
challenged with calcium ionophore produced almost exclusively LTs, whereas EXC4 
formation was favoured over LTC4 when the eosinophils were incubated with 
arachidonic acid(147). Eoxins appears to increase the vascular endothelial cell 
permeability leading to formation of edema, a feature of inflammation(147,148). In 
essence, several lines of evidence indicate an increased 15-lipoxygenase activity in the 
lungs and airways. However, it is unclear which role 15-LO pathway plays in the 
asthmatic airway inflammation.  
 
1.5.5 Lipoxins and Resolvins 
Lipoxins, resulting mainly from the interaction between 5- and 15-LO pathways, are 
anti-inflammatory endogenous lipid mediators involved in the resolution of 
inflammation and are present in the airways of asthmatic patients. Diminished 
biosynthesis of these counter-regulatory mediators has been identified in severe forms 
of human respiratory illness, including aspirin-intolerant asthma(149) and severe 
steroid-dependent asthma(150). Lipoxins generated in mouse models of asthma are 
potent regulators of airway inflammation and hyper-responsiveness. Furthermore, 
lipoxins block oedema formation and reduce the levels of pro-inflammatory mediators 
IL-5, IL-13, prostanoids and cysteinyl leukotriene(151).  
Resolvins were so-named as they were proved to be potent regulators of 
resolution. Resolvin E1 is produced in healthy individuals and is increased in the 
plasma of individuals taking aspirin(152). It is possible that disruption of formation of 
Figure 5. Biosynthesis of 15-HETE and eoxins via 15-Lipoxygenase pathway 
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these pro-resolution mediators by either COX or lipoxygenase inhibitors gives rise to 
delayed resolution and prolonged inflammation(153).    
 
1.6 Airway hyperresponsiveness 
Airway hyperresponsiveness (AHR) is an abnormal increase in airflow limitation 
which may vary over time, often increase during exacerbations and decrease after 
treatment with anti-inflammatory medications(123,154). AHR is a characteristic feature 
of asthma and comprises two components; a persistent and a variable AHR. The 
persistent component is largely attributed to structural changes in the airways 
collectively referred to as airway remodelling. The variable or episodic component is 
related to inflammatory cells and mediators influenced by numerous environmental 
events, i.e. allergens, respiratory tract infections and therapies(155,156).  
Airway responsiveness is quantified as the provocative concentration (PC) or the 
provocative dose (PD) of the stimuli that cause a given fall in forced expiratory volume 
in one second (FEV1)(123,157). The variability in AHR provides insight into 
mechanisms that regulate the airway responses(155). In order to measure AHR, the 
provocative stimuli are differentiated into direct and indirect. The two commonly used 
direct stimuli, histamine and methacholine, act predominantly on the airway smooth 
muscle receptors, histamine 1 (H1) and muscarinic receptors, respectively(156). By 
contrast, indirect provocative stimuli such as exercise, mannitol, allergen, adenosine 
and ASA cause airflow limitation upon stimulation of inflammatory and neuronal cells 
with subsequent release of endogenous mediators that provoke contraction of airway 
smooth muscles(157). 
 
1.7 Airway challenge tests 
Bronchial provocation tests used in the investigation of asthma are now well-
standardized and can offer key information on the therapeutic potential of new agents 
and their anti-inflammatory effects on the airways. Standardized challenge tests, 
performed by experienced investigators, are safe and do not result in risks of persistent 
worsening in asthma or pulmonary function changes. In addition, such interventions 
expand the knowledge about the mechanistic pathways of development and persistence 
of airway inflammation. In the research field, inhaled allergen challenge in subjects 
with mild atopic asthma has gained credibility for assessment of the impact of different 
therapeutics with a very high negative and a reasonable positive predictive value(158). 
 
1.7.1 Methacholine challenge 
Methacholine, a muscarinic agonist, has become widely used clinically to help assess 
the presence and the magnitude of AHR in patients with symptoms consistent with 
asthma who have a normal baseline lung function(159). Methacholine has an excellent 
sensitivity but mediocre positive predictive value for asthma. Thus, a negative 
methacholine challenge excludes current asthma with a high degree of certainty. 
However, a positive methacholine associated with symptoms similar to those which 
occur naturally documents the presence of airway dysfunction and provides a basis for 
asthma therapy(70).  
Several caveats must be considered when interpreting methacholine provocations. The 
most important of these are that the symptoms are current, the resting expiratory flow 
rate is normal and the medications which may affect the airway responsiveness are 
withheld for their biological duration of action prior to challenge(70). Challenge with 
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methacholine is currently more commonly used and is preferred to histamine; the latter 
being associated with more systemic adverse effects, e.g. headache, flushing, and 
hoarseness(160).  
 
1.7.2 Inhaled lysine-acetylsalicylic acid challenge 
The diagnosis of ASA/NSAID-intolerant asthma is based on a reported history of 
asthmatic reactions precipitated or exacerbated by ASA or related NSAIDs. In cases 
without clear history, the diagnosis can be established with certainty only by ASA 
challenge tests. Oral ASA provocation has been used since the early 1970s to confirm 
or exclude AIA. However, this procedure is time-consuming and accompanied with the 
risk of severe bronchial as well as extra-pulmonary and systemic reactions(161). Nasal 
ASA provocation with lysine-ASA is safe and quick, but with rather low sensitivity and 
patients with negative nasal provocation results should therefore undergo bronchial or 
oral ASA challenge tests.  
In 1977, Bianco et al. introduced the inhaled ASA challenge for the diagnosis of 
AIA(162). In a comparative study, the sensitivity of ASA bronchoprovocation has been 
found to be as high as that of the oral ASA challenge, with respect to detection of 
airway obstruction(163). The inhaled lysine-ASA challenge produces no systemic 
reactions and is proved safer as well as quicker to perform than the oral challenge 
test(161). 
 
1.7.3 Allergen challenge 
Sensitized individuals challenged with inhaled allergens can develop either isolated 
early asthmatic responses (EAR)(43) or dual responses  (EAR and LAR)(164). Inhaled 
allergen challenge, with its excellent reproducibility(165), has become an established 
tool that provides invaluable insight into the mechanisms of allergen-induced airway 
responses and inflammation (figure 6). 
The fact that airway inflammation is a primary factor in the pathogenesis of 
allergen-induced asthma has been supported by many observations, e.g. LAR correlates 
with allergen-induced increase in airway eosinophilia; in bronchoalveolar lavage  
(BAL)(166) and sputum analyses(167). In addition, AHR itself has been shown to 
correlate positively with BAL eosinophils and metachromatic cells(168). Consequently, 
allergen-induced AHR and airway eosinophilia, with or without other markers of 
airway inflammation, have become the major components of most standardized 
allergen challenge studies. In standardized protocols for allergen challenge, increasing 
doses of specific allergen are inhaled until a 20% fall in FEV1 is observed and PD20 as 
the end-point measurement is determined(169). 
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1.8 Sputum induction 
Since the introduction of a first standardized sputum induction by Pin et al. in 1992 
[187], the method has become applicable as a research and increasingly clinical tool to 
evaluate the presence, type and extent of the asthmatic airway inflammation. The 
induction procedure is relatively non-invasive and safe(170-174) with a good short-
term repeatability of the induced sputum cell analysis(175-177). The mechanisms 
whereby inhalation of hypertonic saline results in bronchoconstriction are unknown. 
However, activation of airway mast cells [192] or sensory nerve endings may be 
involved(178). Cells obtained from induced sputum have been shown to reflect the 
findings from bronchial samples (bronchial wash, lavage and to a lesser extent 
biopsies)(179). 
Cell counts in induced sputum samples are usually reported as percentage of non-
squamous cells rather than the absolute number of cell. The percentage outcome is 
preferred due to the variation in techniques (which either use the whole expectorate or 
selected plugs) and the extent to which saliva may dilute the sputum(179). The extent 
of sputum eosinophilia is shown to be related to measures of air flow obstruction and 
AHR(180-182). Furthermore, increasing emphasis on characterization of the 
eosinophilic and non-eosinophilic asthmatic phenotypes facilitates mechanistic studies 
of these distinct phenotypes and their therapeutic aspects e.g., the eosinophilic 
phenotype which is characterized by more subepithelial fibrosis is more responsive to 
inhaled corticosteroids (ICS)(183-186). In connection with paper I and IV, cells in the 
induced sputum were studied. 
 
 
Figure 6. Allergen bronchoprovocation in an atopic 
asthmatic subject with early and late asthmatic reactions 
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1.9 Fractional exhaled nitric oxide (FE NO) 
Measurement of fraction of exhaled nitric oxide (FENO), as a noninvasive test and 
surrogate marker of inflammation, has facilitated the assessment of underlying 
inflammation in asthma. Nitric oxide, predominantly produced by inducible nitric oxide 
synthase (iNOS), is elevated in asthmatic subjects(187) and is thought to be primarily 
due to an increased expression of iNOS in airway epithelial and inflammatory 
cells(188).  
In asthma, numerous studies have demonstrated a close correlation between 
FENO and eosinophilic airway inflammation measured in BAL, bronchial biopsies and 
induced sputum(189,190). Elevated FENO has been found to correlate significantly 
with blood eosinophilia in atopic subjects. Furthermore, levels of FENO have been 
found to increase when asthma control deteriorates and to significantly decrease when 
oral or inhaled corticosteroid therapy is administered. In addition, FENO correlates 
significantly with the changes in AHR and asthma symptoms. After being extensively 
studied over the last two decades, FENO has evolved from its role as a research method 
into clinical use in the field of asthma. However, further studies are needed to better 
define the use of FENO in different clinical settings(191). 
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2. Aims 
The general objective of this thesis was to investigate the impact of inflammatory 
mediators, with emphasis on eicosanoids, on the inflammatory and functional airway 
responses, under constitutive (baseline) and triggered conditions in subjects with 
asthma, in particular ASA/NSAID-intolerant and allergic phenotypes. In the studies 
documented here, several questions were considered to shed light on and to find 
answers for. 
 
1. In the search for new diagnostic possibilities of AIA, one of the important 
questions was whether measurements of CysLTs in different body matrices, at 
baseline and under triggered bronchoconstriction following exposure to ASA, 
could serve as a new diagnostic opportunity for this distinct asthmatic 
phenotype More specifically, the diagnostic potential of measurements of LTE4 
in induced sputum, saliva and ex vivo stimulated blood were to be evaluated in 
comparison with that in urine. 
 
2. Can the capacity of eosinophils to produce 15-LO pathway products be used as 
a biomarker for AIA? Does the ex vivo responsiveness of eosinophils to COX 
inhibition in subjects with AIA differ from that of eosinophils derived from 
subjects with other asthma phenotypes and healthy volunteers with regard to the 
release of key arachidonic acid metabolites, in particular those related to 
activity of the two major lipoxygenase pathways, 5-LO and 15-LO?  
 
3. Which COX isoenzyme, COX-1 or COX-2, is catalyzing the biosynthesis of the 
bronchoprotective and bronchoconstrictive/pro-inflammatory prostaglandins in 
asthma? The thesis, therefore, aimed at evaluating the role of COX-1 and COX-
2 in the biosynthesis of PGD2 and PGE2 under basal conditions and during 
heightened airway inflammation and responses after inhaled allergen 
provocation. 
 
4. Does treatment with selective COX-2 inhibitors impose a risk of causing 
deterioration of asthma?  Are there any consequences of COX-2 inhibition on 
airway obstruction or airway inflammation during asthma exacerbations?   
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3. Methodological aspects 
 
3.1 Study subjects 
The baseline characteristics of all subjects are displayed in table 1 and further details 
are described in the individual papers. All subjects were never smokers or non-smokers 
for the last two years prior to the study start with a smoking history of less than five 
pack years. The asthmatic subjects had stable asthma and had not suffered respiratory 
infections in the four weeks prior to inclusion.  
 
 
 
  
Paper Subjects 
number, group 
Age  (year) 
Mean (range) 
 
Gender 
F/M 
ICS budesonid eqv µg 
mean (range) 
FEV1% predicted 
mean  (range) 
I 11 AIA 
10 ATA 
8 IA (Atopic) 
45 (27-56) 
46 (35-63) 
35 (19-55) 
8/2 
6/5 
4/4 
 
640 (150-1500) 
400 (200-400) 
- 
85 (73-98) 
97 (84-110) 
102 (93-112) 
II 7 AIA 
9 SA 
8 MA 
8 Healthy 
39 (23-49) 
46 (30-60) 
38 (24-58) 
36 (23-48) 
 
4/3 
5/4 
7/1 
5/3 
560  (160-1200) 
2018  (1280-3200) 
495  (320-800) 
- 
95  (73-123) 
76  (40-99) 
99  (82-122) 
117  (107-133) 
III 6 AIA 
6 ATA 
6 IA 
Healthy 
42 (24-57) 
29 (23-45) 
30 (23-51) 
29 (25-39) 
3/3 
4/2 
2/4 
3/3 
590 (160-1200) 
410 (320-720) 
- 
- 
86 (68-117) 
93 (79-108) 
104 (97-113) 
- 
 
IV 16 Atopic asthma 34  (23-50) 
 
5/11 - 103  (91-118) 
  
 
 
 
 
 
3.2 Ethical aspects 
Approval from local ethics committee at Karolinska University Hospital was gained for 
all four studies documented in this thesis (Dnr 2003 KI syd 518/3, 04-470/1-4, 
2007/865-31, 2006/728-31/2 and 2009/959-31-4) Prior to start of each study, oral and 
written informed consent were obtained from all subjects.  
 
 
 
 
 
 
AIA, ASA/NSAID-intolerant asthma; ATA, ASA/NSAID-tolerant asthma; IA,  Intermittent 
asthma; SA, Severe asthma; MA, Mild asthma; F, Female; M, Male, ICS; inhaled corticosteroid 
Table 1. Subject characteristics of all papers 
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3.3 Study design 
 
3.3.1 Paper I 
The study comprised a screening and two study visits (Figure 7). During the screening 
visit, informed consent was obtained followed by clinical assessment and spirometry to 
determine eligibility of the subjects prior to study enrollment. On a later visit, baseline 
measurements of FENO and spirometry were followed by collection of urine, saliva and 
induced sputum. On a further visit (3-10 days after the baseline visit), inhaled lysine-
ASA provocation was performed after which asthmatic subjects were assigned to two 
groups, AIA (n=11) and aspirin-tolerant asthma (ATA) (n=10). Before the challenge, 
FENO was measured, saliva and urine were collected and blood was drawn.  
During the challenge spirometric measurements were performed and saliva and 
urine were collected hourly. Blood and saliva samples were taken up to two hours and 
urine samples were collected up to three hours after the end of the challenge. CysLTs, 
LTB4 and 9α,11β-PGF2 were measured with enzyme immunoassay (EIA).  In a parallel 
experiment, saliva and urine collected from eight atopic subjects with mild asthma were 
analyzed to study the impact of inhaled allergen on the excretion of leukotrienes.  
 
                    
 
 
 
 
 
 
 
 
Figure 7. Study design paper 1 
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3.3.2 Paper II 
The study described in paper II consisted of two clinic visits. During an initial visit, 
clinical assessment of the subjects was performed, measurements of dynamic 
spirometry and FENO were determined and blood was drawn for differential cell 
counts. The asthmatic subjects as well as the healthy volunteers underwent skin prick 
testing (if not previously performed) against common aeroallergens. On the second 
visit, 100 mL venous blood was drawn for isolation of eosinophilic granulocytes. In 
highly purified eosinophils, the biosynthesis of key 5- and 15-LO products was studied 
in presence or absence of ASA.  
 
3.3.3 Paper III 
The study documented here was randomized cross-over and single-blind with a 2-week 
washout separating two treatment periods (Figure 8). Each period consisted of five 
clinic visits in the morning on consecutive weekdays. Baseline pre-treatment 
measurements, done in the mornings of the first 2 study days, were followed by 
treatment with the study drug, celecoxib 200mg b.i.d. or placebo b.i.d., administered as 
capsules on study days 2–5 during each period, with the first dose taken immediately 
after baseline measurements on the day 2. 
On an initial screening visit, informed consent was obtained and a clinical 
assessment including spirometry was done. Blood was drawn for routine haematology 
and to ensure normal liver and renal function. For safety reasons, tolerance to celecoxib 
was confirmed  (see details in oral and airway challenges) and the test was followed by 
a 1-week washout. One urine sample from each subject was collected at the unit in the 
morning (the first morning urine was voided at home). The voided urine volume was 
measured and the samples were stored at -70°C until assayed. The subjects were 
instructed not to take any food or beverage, except water, within 1.5 hour before 
sampling. Subjects were also informed to wash their mouth with water before 5mL of 
whole saliva was collected into a plastic tube and was stored at -70°C until assayed.  
A control group of six healthy individuals were also recruited to participate in the 
celecoxib study period, but did not receive placebo, to determine the effects of 
celecoxib on urinary prostaglandins. Measurements of FEV1 and FENO were performed 
and urine and saliva were collected. The levels of urinary eicosanoid metabolites and 
salivary PGE2 were performed by tandem LS/MS/MS and enzyme immunoassay 
(EIA), respectively. 
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3.3.4 Paper IV 
The study described in paper IV (figure 9) comprised a screening phase followed by a 
randomised two-period, cross-over comparison between active treatment with 
etoricoxib, and an untreated study period with identical design. On screening, baseline 
characteristics including FENO, FEV1, skin prick testing, total and specific IgE for the 
allergens and current airway sensitivity to methacholine and allergen, were obtained. 
The allergen challenge tests during this study were followed by a washout period of at 
least 14 days. Etoricoxib tablets 90 mg were administered once daily for 10-13 days 
with the first dose taken in the clinic on study day 1, i.e. after baseline assessments on 
the first day of the treatment period. Methacholine bronchoprovocation was performed 
on the first and the penultimate day of each period to determine PD20FEV1. An allergen 
inhalation challenge was then performed on the last day of each period to determine the 
impact of the treatment/no treatment on the airway sensitivity to allergen. Sampling of 
blood and induced sputum was performed on study day 1, i.e. at baseline, and on the 
last two days, study day 2 and 3, of each period. Sputum induction was performed one 
hour and six hours after the maximum FEV1 fall following methacholine and allergen 
provocation, respectively. Urine was collected before the start of allergen 
bronchoprovocation, and one and two hours after the maximum FEV1 fall. 
 
 
Figure  8. Study design paper III. Study day 1 and 2 = baseline days, R = Randomization 
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3.4 Measurements of lung function 
Measurements of lung function using a spirometer (Jaeger Masterscope, Intramedic 
AB, Bålsta, Sweden) have been a key part of all four studies documented in this thesis. 
This test provides objective, reproducible and reliable information wherein normal 
values depend on the height, age, gender and ethnic group of the subjects. It has been 
an essential tool to screen, define the respiratory impairment, quantify the severity and 
monitor the changes in the lung function and airway responses as well as follow-up of 
the subjects. The major measurements comprised the forced expiratory volume in one 
second (FEV1), vital capacity (VC), forced vital capacity (FVC) and FEV1:FVC ratio. 
The peak expiratory flow rate (PEFR) was measured with a simple handheld device 
given to the subjects for follow-up purposes. The standards of interpretations have been 
performed in accordance with the recommendations of the American and European 
Thoracic Societies(192). 
 
3.5 Measurements of fractional exhaled nitric oxide 
Subjects included in the studies have undergone standard measurements of FENO 
according to the guidelines of American and European Thoracic societies to determine 
nitic oxide (NO) at baseline and the changes along the course of the studies. Using a 
chemoluminescence analyser  (NIOX, Aerocrine AB, Sweden), the subjects inhaled to 
their total lung capacity and immediately exhale at a constant flow of 50 ml/s  (against 
resistance to exclude possible contamination with nasal NO by means of velum 
closure) until a 3-second NO plateau was reached at the end of the exhalation(193). 
 
Figure 9. Study design paper IV; two randomised periods etoricoxib 90 mg q.d. 10-13 
days vs no treatment. * = cumulative allergen challenge, * * = Urine, before, 1 and 2 hours 
after allergen challenge, * * * = Blood before allergen challenge, R = Randomisation 
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3.6 Skin prick testing 
In all four papers, skin prick testing (SPT) has been a part of screening and 
characterization of the subjects. In paper IV, SPT has been an aiding tool, together with 
a suggestive clinical history and serum IgE antibodies, to identify the specific allergen 
used in the airway challenges. Medications were withheld according to standard 
procedures. The test was performed by introducing a small quantity of allergen into the 
epidermis by pricking the skin. 
Standardized extracts of allergens including Dermatophagoides pteronyssinus, 
Aspergillus fumigatus, grass pollen, cat fur, and horse and dog hair (ALK, Sweden) 
were used as well as positive (histamine hydrochloride) and negative control solutions. 
The subjects are evaluated for dermographism and the reactions were recorded after 15 
minutes. The longest diameter of the wheal was measured and used to assess the 
positivity of the skin test (41). 
 
3.7 Saliva sampling and processing 
In Paper I and II, saliva was collected and studied for the levels of leukotrienes and 
prostaglandin E2, respectively. Subjects were informed not to take any food or 
beverage, except water, within 1.5 h before sampling. They were also instructed to 
rinse their mouth with water before collecting 5 mL of whole saliva into a plastic tube 
which was then stored at -70°C. The samples were thawed prior to assay, centrifuged at 
1500g for 10 min (+4°C) and the supernatant was subsequently analyzed.  
 
3.8 Sputum induction and processing 
Sputum induction and processing was performed using hypertonic saline and in 
accordance with the European Thoracic Society guidelines(194,195). Subjects were 
given salbutamol 0.2 mg and provided that FEV1 ≥ 70% of predicted, aerosol 
containing increasing concentrations of sterile saline (3, 4, and 5%) was administered 
through an ultrasonic nebulizer for seven minutes each, through a mouthpiece without a 
valve or nose clip (DeVilBiss Ultraneb 3000, Dolema AB, Sweden). For safety reasons, 
FEV1 was measured after each period of inhalation. Contamination with saliva and post 
nasal drip was minimized by rinsing the mouth and blowing the nose. Sputum was 
expectorated into a sterile container. 
There are two methods for processing the expectorate: selecting viscid or dense 
portions (used in paper IV) and processing the entire expectorate (used in paper I) 
comprising sputum and variable amounts of saliva. Selected sputum has the advantage 
of having a squamous cell contamination of less than 5%. Squamous cell contamination 
of ≥20% of all recovered cells is associated with lower reproducibility of the cell 
counts(194). Cytospins are prepared from the cell pellet and differential cell counts are 
established. The cell differential counts are expressed as a percentage of the total 
number of non-squamous cells. Squamous cells are expressed as a percentage of the 
total cell number. 
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3.9 Urine collection and correction of dilution 
In paper I, III and IV, urine was collected for measurement of metabolites of 
eicosanoids. The first morning urine was voided at home and urine samples were 
collected upon visits according to the study designs. The voided urine volumes were 
measured and the samples were stored at -20°C (paper I) and -70°C (paper III and IV) 
until assayed. The measurements of leukotrienes and prostanoids were related to 
creatinine concentration to compensate for the diuresis. The alkaline picrate added to 
urine reacts with the creatinine resulting in a red color the intensity of which is 
determined spectrophotometrically at 490 nm. Following acidification, the color 
changes and the difference in adsorbance before and after adding the acid is 
proportional with the creatinine concentration which is expressed as mmol/L. The 
metabolites were then presented as ng/mmol of creatinine. 
 
3.10 Oral and bronchial provocations 
The provocations were carried out under direct supervision of experienced physicians 
skilled in performing provocation. A clinical assessment was done to exclude serious 
reactions in connection with previous provocations, serious heart, liver or kidney 
diseases, respiratory tract infection within four weeks prior to challenge, pregnancy and 
current treatment with β-blockers. Subjects were instructed about the drug withdrawal 
before the intervention. Conditioned that the subjects were in a stable clinical condition 
and had a baseline EFV1 of at least 70% of predicted value, the challenge was initiated. 
Equipment for emergency resuscitation was readily available and an intravenous line 
was attached. 
 
3.10.1 Oral provocation with celecoxib 
In paper III, subjects with AIA were tested for safety reasons with regard to the 
tolerance of the study medication, celecoxib. Two doses of celecoxib, each of 100 mg, 
were given 1 hour apart followed by a 2-hour observation. Conditioned that no reaction 
was observed, the study proper was started after a 1-week washout. 
 
3.10.2 Bronchial challenge with lysine-acetylsalicylic acid  
Inhaled ASA challenge tests were used in the papers I, II and III. Baseline FEV1 and 
PEFR measured as the best of three efforts.  If the baseline FEV1 was >70% of 
predicted, the test was started with seven breaths of nebulized saline (0.9% sodium 
chloride). Provided that post-saline FEV1 was above 60% of predicted and had not 
decreased >10% after 20 minutes, consecutive increasing doses of lysine-ASA were 
inhaled through a dosimeter-controlled jet nebulizer  (Spira Elektro 2, Respiratory Care 
Center, Hameenlinna, Finland) every 30 minutes with FEV1 measurements every 10 
minutes after each ASA-dose (table 2). The provocation was interrupted when FEV1 
had fallen ≥20% from the post-saline baseline value, or if strong symptoms were seen, 
as well as when the maximum cumulative ASA-dose was reached. After a positive 
reaction, spirometry was carried out every 15 min (for at least one hour) until FEV1 had 
returned to within 90% of the post-diluent baseline value. The challenged subjects were 
advised to record PEFR with a handheld device hourly and in the case of airway 
symptoms instructed to use rescue medications at predefined level of drop in PEFR or 
contact the hospital.  
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Table 2. Protocol for lysine-ASA bronchial challenge(161) 
Lysine-ASA 
Conc.  (M) 
Number of 
breaths 
Dose 
(µmol) 
Cumulative dose  
(µmol) 
0.1 1 1 1 
0.1 2 2 3 
0.1 7 7 10 
1.0 2 20 30 
1.0 7 70 100 
1.0 8 80 180 
1.0 12 120 300 
1.0 30 300 600 
 
 
3.10.3 Inhaled allergen challenge 
In paper IV, all subjects underwent inhaled challenges with a specific allergen, upon an 
initial screening and in the end of either periods of the study. Determination of post-
saline baseline value of FEV1 was done as mentioned in the inhaled lysine-ASA 
challenge. Using a dosimeter-controlled jet-nebulizer (Spira Elektro 2, Respiratory 
Care Center, Hameenlinna, Finland), the challenge was started by inhalation of the 
lowest dose of allergen followed by incremental doses administered every 20 minutes 
(table 3). Single spirometric measurement at 18 minutes after each dose increment was 
obtained. The provocation was terminated when FEV1 had fallen at least 20% from the 
post-diluent baseline, or the maximum dose of allergen was reached (7100 SQ). After a 
positive reaction, spirometry was carried out every 15 min (for at least one hour) until 
FEV1 had returned to within 90% of the post-diluent baseline value.  Before leaving the 
clinic, the subjects were provided with a handheld PEFR device and instructed at which 
predefined level of drop in PEFR or in FEV1 they should use rescue medication and/or 
contact the hospital in case of a severe late asthmatic reaction. 
 
Table 3. Protocol for allergen bronchoprovocation(196)  
Allergen conc. 
SQ/mL 
Number of 
breaths 
Dose 
SQ units 
Cumulated dose 
SQ units 
1000 1 7 7 
1000 2 14 21 
1000 7 50 71 
10000 2 142 213 
10000 7 497 710 
100000 2 1420 2130 
100000 7 4970 7100 
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3.10.4 Methacholine provocation 
If the baseline FEV1, measured as the best of three efforts, was ≥70% of predicted, the 
post-diluent baseline was determined and the test was started provided FEV1 did not 
deviate by more than 10% from the pre-diluent value. By using increasing number of 
breaths and different methacholine solutions, doubling increments of the dose of 
methacholine were administered through a dosimeter-controlled jet-nebulizer (Spira 
Elektro 2, Medela, Medical AB,Sweden). The methacholine solution was inhaled every 
three minutes. FEV1 was obtained as a single measurement at 2.5 minutes after each 
dose increment (table 4). 
The provocation was terminated when FEV1 had fallen at least 20% from the 
post-diluent baseline, or the maximum dose of methacholine was reached (3635 µg). 
After the challenge the patients were observed until FEV1 had returned within 90% of 
baseline, either spontaneously or after inhalation of β2-agonist.  
 
Table 4. Protocol for dosing of methacholine(196) 
Methacholine conc. 
mg/mL 
Number of 
breaths 
Dose 
 (µg) 
Cumulated dose 
 (µg) 
1 2 14.2 14.2 
1 4 28.4 42.6 
1 8 56.7 99.3 
8 2 114 213.3 
8 4 227 440.3 
8 8 454 894.3 
64 2 909 1803 
64 4 1818 3621 
64 8 3635 7256 
 
3.11 Enzyme Immunoassay (EIA) 
In paper I, measurements of CysLTs, LTB4 and 9α,11β-PGF2 were performed in 
serially diluted aliquots of the respective samples by enzyme immunoassays  (Cayman 
Chemical, Ann Arbor, Michigan, USA). Concentrations of LTE4 and 9α,11β-PGF2 in 
urine were given as ng/mmol creatinine. For analyses of LTB4 and CysLTs in sputum, 
the same concentration of DTT (0.04%) as in the sputum supernatant was added to the 
standard curve and enzyme immunoassay buffer. Levels of CC-16 in serum were 
determined using an enzyme-linked immunosorbent assay for serum CC-16 from 
BioVendor Laboratory Medicine (Brno, Czech Republic).  
In paper II, measurement of PGE2 in saliva was performed with an enzyme 
immunoassay (EIA) from Cayman and expressed as pg/mL of saliva. The detection 
limit was 15pg/mL. The antibody had <0.01% cross-reactivity with other primary PG 
of the two-series and their immediate metabolites, but 43% cross-reactivity with PGE3, 
20% with PGE1 and 1–3% for isoprostanes E2 and F2, respectively.  
In paper III, levels of EXC4, LTC4 and 15-HETE were determined using EIA according 
to the protocol of the manufacturer (EXC4 and 15-HETE from Cayman Chemicals, 
LTC4  from GE Healthcare). 
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3.12 Tandem liquid chromatography/tandem mass spectrometry 
In paper II, III and IV, the metabolites of eicosanoids are measured using tandem liquid 
chromatography/tandem mass spectrometry (LC/MS/MS). Liquid chromatography 
coupled to mass spectrometry is the most suitable technique for separation of multiple 
eicosanoid isomers (e.g, tetranor PGDM and PGEM metabolites) found in urine in low 
level.  Levels of eicosanoid metabolites in urine were normalized to creatinine levels or 
integrated over time (paper IV) in order to adjust for variations in the urine 
production(68,197,198). 
 
3.13 Isolation and incubation of eosinophils 
An initial centrifugation at 400 x g for 15 min was performed. Thereafter, the upper 
phase was discarded, and the lower phase was collected and subjected to dextran 
sedimentation for 30 min at 200C. After sedimentation, the upper phase containing 
white blood cells was centrifuged once at 400 x g for 10 min. The pellet was suspended 
in lysis buffer (100 mM NH4Cl, 10 mM Tris-HCl, pH 7.4) and incubated for 30 min at 
room temperature to remove erythrocytes. Density gradient centrifugation using 
lymphoprep, was performed after incubation. The polymorphonuclear fraction, 
containing neutrophils and eosinophils was collected and subjected to magnetic cell 
sorting. Eosinophils were isolated by negative selection using CD16 antibodies 
conjugated to magnetic microbeads.    
In paper II, isolated eosinophils were resuspended in PBS at a concentration of 1 
x 106 cells per mL and incubated for 5 min, in the presence or absence of lysine-aspirin  
(200 µM), before further incubation with arachidonic acid  (10 µM) or A23187  (1 µM) 
for 10 min. The reactions were terminated by rapid cool off on ice and centrifugation at 
1,200 x g, 5 min. Supernatants were stored at -80°C prior to analysis. Due to the low 
differential count of eosinophils in healthy subjects, and the order in which the 
incubations were carried out, insufficient amounts of eosinophils were recovered for 
comparable analysis of LTC4 in the group with healthy volunteers.   
 
3.14 COX-1 and COX-2 assays 
In paper IV, measurements of thromboxane generation in clotted blood for COX-1 
activity, and LPS-induced formation of PGE2 in leukocytes for COX-2 activity were 
performed.  
Levels of PGE2 produced in human whole blood following stimulation with LPS were 
used as an index of the degree of COX-2 inhibition. Following collection into heparin 
containing tubes, 500µl aliquots of fresh blood were incubated with LPS at a final 
concentration of 100µg/ml, or the relevant negative control, for 24 hours at 37°C. At 
the end of the incubation, blood was centrifuged at 1200g for 5 minutes in order to 
obtain plasma which was stored at -80°C before immunoassay for the measurement of 
PGE2. 
To assess COX-1 activity, blood was collected into vacutainers containing no 
anticoagulants, and 500µL aliquots were allowed to clot for one hour at 37°C. 
Thereafter, serum was separated by centrifugation and stored at -80°C. Thromboxane 
(TXB2) levels were later measured in the serum by enzyme-immunoassay (EIA)  
(Cayman Chemical, Ann Arbor, MI, USA). 
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3.15 Statistical analysis 
In paper I, the non-parametric tests, Mann–Whitney rank-sum and Wilcoxon signed 
rank, were used in connection with the levels of the mediators. Repeated measures 
ANOVA were applied to determine the differences between the study groups with 
regard to the eosinophil counts in induced sputum and data were described as means 
and interquartile ranges (IQR). The student’s t test was applied for assessment of the 
inter-group differences in the baseline FENO. The results of FENO were expressed as 
means and standard deviations (SD). Repeatability of FENO measurements and levels 
of mediators in saliva and urine was considered to quantify measurement error using 
within-group correlation coefficient between the baseline values obtained on visit 1 and 
on the later visit  (visit 2) prior to the challenge. 
A p-value of < 0.05 was considered significant. Data in this paper are displayed as 
medians and 10th, 25th, 75th and 90th percentiles 
In paper II, the sets of 15-HETE, EXC4 and LTC4 data were normally 
distributed according to the Kolmogorov-Smirnov test. Within-group comparisons and 
between-group comparisons were performed using Student’s paired and unpaired t-test, 
respectively).  All correlations were done using the Spearman Rank test as certain 
clinical characteristics were not normally distributed. A p-value of <0.05 was 
considered statistically significant. 
In paper III, the levels of the metabolites on three consecutive days of treatment 
with celecoxib or placebo were compared with the mean baseline (the 2 preceding 
baseline days during each period). Mean levels of urinary PGDM during the 
consecutive days of treatment (days 3–5), expressed either as raw values or in percent 
of baseline, were used to assess the effect of treatment with celecoxib and placebo. The 
median (25th–75th percentiles) percent inhibition of PGEM, PGIM and TXM during the 
3-day treatment with celecoxib was compared with the placebo. Mean (SEM) FEV1 
percent predicted and median (25th – 75th percentiles) FENO days 3–5 after treatment 
with celecoxib were compared with the consecutive treatment days with placebo. For 
lung function, paired t-test was used. Medians and (25th-75th percentiles) were used to 
determine the gender differences, with regard to excretion of metabolites at baseline 
and after treatment. Using the Wilcoxon signed-ranks test for the cross-over periods 
and the Mann–Whitney rank sum test or Kruskal–Wallis one way analysis of variance 
on ranks for between-group comparisons, the effects of treatments on urinary 
metabolites were analyzed. 
In paper IV, PD20FEV1 values for methacholine and allergen were 
logarithmically transformed, paired t-test was performed and data were presented as 
geometric mean and range.  Analysis by RM-ANOVA within and between the study 
arms was performed to determine the changes in the percentage of differential cell 
counts, and results were presented as mean and SEM.  Paired t-test was used to 
determine changes in lung function, blood pressure, urinary metabolites, blood COX-
assays, and FENO (log tansformed values).   
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4. Results and discussions  
 
4.1 Paper I 
Baseline levels of CysLTs in saliva, sputum, ex vivo stimulated blood and urine are 
higher in ASA-intolerant asthmatics than in subjects with ASA-tolerant asthma 
lending further support to a deviated leukotriene metabolism with overproduction 
of CysLTs  (figure 10) 
The clinically well-characterized asthmatic subjects were assigned to either 
ASA/NSAID-tolerant or intolerant groups based on the outcome of the inhaled ASA 
challenge test. The two resulting groups, AIA and ATA, demonstrated a high degree of 
similarity in their baseline characteristics. However, ASA/NSAID-intolerant asthmatics 
had a propensity for higher eosinophil counts in induced sputum and higher FENO 
values despite having larger doses of inhaled corticosteroids as well as further treatment 
with leukotriene receptor antagonists known to reduce FENO levels(191). This provides 
further support for the more pronounced eosinophilic inflammation associated with 
ASA/NSAID-intolerant asthma. 
Compared to ASA/NSAID-tolerant asthmatics, subjects with AIA had higher 
basal LTE4 in saliva, sputum supernatant and in ex vivo stimulated whole blood. Unlike 
LTE4, baseline levels of LTB4 in those biological matrices were not significantly 
different between the two groups. In subjects with AIA, the finding of raised baseline 
CysLT levels in ex vivo stimulated whole blood and saliva is new, whereas the 
observation of increased level of basal LTE4 in induced sputum replicates the results of 
only one previously reported study(199). Increased levels of urinary LTE4 in subjects 
with AIA confirmed previous data and served to validate this study.  
The increased expression of LTC4 synthase in eosinophils has been suggested to 
explain the chronic basal CysLT overproduction and impaired baseline lung function in 
subjects with AIA(37). However, here the basal sputum LTE4 levels when expressed 
per million eosinophils, were not significantly different in AIA and ATA subjects 
suggesting that the raised basal CysLT levels in AIA may be explained by increased 
number of eosinophils rather than over-activation of eosinophils per se. 
In this study, ASA/NSAID-intolerant asthmatics were for the first time shown to 
have higher baseline levels of salivary CysLTs than those with ATA. It has been 
reported previously that inhibition of 5-LO pathway has an inhibitory effect on the 
salivary leukotriene levels(200). With regard to the leukotriene pathway products, the 
study results support the proposal that saliva may provide relevant and complementary 
information to current standards in asthma management as a non-invasive aiding tool 
for assessment of the inflammatory changes and the response to therapeutics that affect 
this particular pathway in subjects with AIA.   
In a previous study, LTB4 was detectable in exhaled breath condensate only in 
the presence of saliva(201) indicating that the salivary leukotrienes may serve as a 
possible contributory source of these mediators in other biological matrices collected 
orally. In this study, the possible contribution of saliva to the leukotriene content of 
sputum in both AIA and ATA subjects was, however, estimated to be equal as 
squamous cell counts in induced sputum displayed no difference between the two 
groups. The increments in excretion of LTE4 in urine that, as expected, followed ASA- 
and allergen-induced bronchoconstriction were, however, not associated with increased 
CysLT levels in saliva after either challenge suggesting that the quantified salivary 
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LTE4 is unlikely to mirror direct systemic overflow from the bloodstream. Further 
studies are required to define the cellular source of salivary leukotrienes.  
This is also the first time that whole blood from subjects with AIA has been 
found to display an increased capacity for ionophore-stimulated CysLT production. 
Measurements of the mast cell-derived PGD2 metabolite 9α,11β-PGF2 provided further 
insight into the possible source of the increased baseline production of CysLTs. The 
basal urinary excretion of the early appearing PGD2 metabolite, 9α,11β-PGF2, was not 
significantly different between the study groups regardless of sensitivity to 
ASA/NSAIDs confirming the results of previous studies(87). Eosinophils may serve as 
a possible contributory source of CysLTs as AIA is characterized by a higher degree of 
eosinophilia.  In contrast, the association between increased urinary excretion of both 
PGD2 metabolites and CysLTs after ASA-induced bronchoconstriction supports the 
mast cell as the source of these mediators during the intolerance reaction. 
A principal strength of this study was the status of the asthmatic subjects with well-
defined characteristics and a diagnosis of AIA verified with an inhaled ASA challenge 
test at the time of the study. 
In conclusion, higher baseline levels of CysLTs were found in saliva, induced 
sputum, ex vivo stimulated blood and urine in AIA than ATA. However, LTB4 levels 
exhibited no differences between the two groups. This provides an additional support 
for a deviated leukotriene metabolism with selective overproduction of CysLTs. The 
higher salivary CysLT levels in AIA is a new finding that needs to be explored as a 
clinically convenient biomarker of AIA and other diseases associated with increased 
production of leukotrienes(202). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Baseline levels of LTE4 and LTB4 in saliva, induced sputum and 
plasma (from whole blood stimulated ex vivo) from subjects with aspirin-
intolerant asthma (AIA) and aspirin-tolerant asthma (ATA). 
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4.2 Paper II 
The 15-LO pathway may contribute to asthma pathogenesis. The eosinophils are 
likely to be the main source of mediators of the 15-LO pathway, the biosynthetic 
activity of which is in part attributed to increased numbers of the cells, but also 
enhanced eosinophil function. 
Despite the characteristic eosinophilia in AIA, lipid mediator biosynthesis in 
isolated eosinophils have not been characterised before in this particular group of 
patients. The purpose of this explorative study was to shed light on the capacity of 
eosinophils to produce 15-LO pathway products and to determine whether such 
potential eventually could be used as a biomarker for AIA.  
In this study, the first assessment of the biosynthesis of key 5- and 15-LO 
products was performed in highly purified peripheral blood eosinophils from subjects 
with AIA. Among the four groups of this study, subjects in the group with severe 
asthma were older than those in the other three groups and had a higher inhaled 
corticosteroid dose and a lower lung function than the two other asthmatic groups. 
Levels of FENO and number of eosinophils in peripheral blood were higher in the 
groups with severe asthma (SA) and AIA than the group with mild asthma (MA). 
However, no significant difference in the blood eosinophils was found between SA and 
AIA.  
The release of 15-HETE and EXC4, both in the presence and absence of lysine-
aspirin were significantly correlated with total number of blood eosinophils. Levels of 
15-HETE in particular showed significant correlations with the lung function and 
exhaled NO. Moreover, EXC4 levels correlated with the lung function when 
eosinophils were pre-incubated with lysine-ASA. 15-LO-1 is expressed, in addition to 
eosinophils, airway epithelial cells, alveolar macrophages, dendritic cells and 
reticulocytes, even in mast cells and might be of importance for the function of mast 
cells in asthma(137). 
Eosinophils in AIA subjects were shown to possess the property to synthesize the 
novel 15-LO product EXC4 which exhibited higher levels when the eosinophils were 
stimulated in the presence of ASA. Under these conditions, the eosinophils in AIA and 
severe asthma behaved in a similar fashion and also demonstrated an increased release 
of both LTC4 and 15-HETE. The similar effects of ASA on arachidonic acid-induced 
EXC4 and 15-HETE release on the one hand, and ionophore-induced LTC4 release on 
the other hand, are unlikely to be explained by the effects of ASA on the activity of 15-
LO pathway. As EXC4 and LTC4 release were similarly affected by lysine-ASA in both 
AIA and SA subjects, it is also unlikely that these results are attributed to the specific 
intolerance reaction to ASA that occurs in AIA. The most likely explanation for the 
effect of ASA seems therefore to be the COX inhibition with subsequent abolishment 
of PGE2, known to have a negative regulatory impact on the release of inflammatory 
mediators(203-205). Furthermore, significant correlations are found between the levels 
of EXC4 and 15-HETE, and blood eosinophil counts. The magnitude of the differences 
in capacity for mediator production between the groups is in fact greater than perceived 
when levels are expressed per million cells (Figures 1-3). The released amounts of 15-
HETE in mild asthmatic or healthy subjects corresponds to 50nM per litre blood 
compared to 1µM per litre blood in severe or ASA/NSAID-intolerant asthmatics.  
In addition to higher eosinophil counts in AIA and SA, increased numbers of 
hyperactive hypodense eosinophils contribute to this heightened 15-LO activity in these 
two groups of asthmatics. Blood eosinophilia is known to be associated with greater 
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proportion of hypodense eosinophils(206) which in turn is increased in asthmatics and 
related to its severity(207).  
With regard to the extended analysis of eicosanoid metabolism in eosinophils 
from two subjects with AIA, another speculative explanation was raised for the 
increased release of LTC4 and EXC4 observed in severe asthma and AIA.  The highest 
level of any primary COX-pathway product found was TXB2 which indicates 
biosynthesis of the platelet-specific arachidonic acid derived mediator TXA2 (208,209).  
The finding of high level TXB2 was unexpected as the eosinophils were highly purified 
and there were no other cells in the suspension that would primarily express TXA2 
synthase. However, leukocytes are known to carry adherent platelets on their 
surface(210). Platelets also express LTC-S and have been shown to produce LTC4 from 
LTA4 provided by other cells(211,212) and a similar mechanism could catalyse the 
formation of EXC4 from its eoxin intermediate. Eosinophils in AIA subjects have been 
shown to have a far greater degree of adherent platelets than subjects with ATA(213), 
and these platelets account for a significant proportion of total 5-LO products. It is 
possible that the EXC4 and LTC4 formed in our suspensions could be derived from 
eosinophils with adherent platelets. The greater production of LTC4 and EXC4 in AIA 
and severe asthma is explained by an enhanced transcellular metabolism of cysteine-
containing products (LTC4 and EXC4) due to platelet-eosinophil interactions (figure 
11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  5- and 15-LO activity via transcellular 
 interactions between eosinophils and platelets 
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This study provides new evidence the 15-LO pathway mediators may contribute 
to asthma pathogenesis. Significant correlations were found between levels of 15-
HETE production and lung function (FEV1) as well as exhaled NO. Levels of 15-HETE 
were high both in severe asthma and AIA. Severe asthmatics had significantly higher 
steroid doses than those of AIA subjects which are, however, suggested to serve as a 
marker of asthma severity(214) rather than to have contributed to the increased 15-LO 
activity. The role for 15-LO products in asthma has been reported previously with 15-
HETE as the major metabolite of arachidonic acid in asthmatic lung tissue(143,144). 
Adult asthmatics display an increased 15-LO activity in the bronchial mucosa 
compared to control subjects(215).  This indicates that the capacity to produce 15-
HETE by eosinophils could be used as a biomarker for asthma severity. An increased 
activity of 15-LO pathway with increased levels of eoxins in exhaled breath condensate 
has also been reported in childhood asthma(216). The ability of 15-HETE to conjugate 
to phosphatidyletanolamine and stimulate ERK phosphorylation in epithelial cells 
results in activation of inflammatory pathways in asthmatic lung tissue(217).   
Overexpression of 15-LO in airway epithelial cells in vitro is associated with increased 
release of proinflammatory cytokines(218). Involvement of 15-HETE has also been 
reported in mucus secretion in humans(219,220). 
In conclusion, the findings in this study suggest that one role of the eosinophils in 
AIA may be to be a major source of 15-LO products. This higher biosynthetic activity 
of 15-LO pathway is in part attributed to increased numbers of eosinophils and the data 
in this study also suggest the contribution of increased numbers of hyperactive 
hypodense eosinophils and enhananced eosinophil function via transcellular 
interactions with platelets to this heightened 15-LO activity in AIA and severe. 
Moreover, the increased 15-LO activity present in AIA and severe asthmatics 
was enhanced further following incubation with ASA suggesting that this effect of the 
latter was not exclusively due to the specific intolerance reaction in AIA, nor was it 
related to the level of steroid treatment. This documentation of EXC4 formation in 
activated eosinophils from asthmatic subjects encourages further explorations of the 
biological role of this novel lipid mediator (figure 12). 
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Figure 12. Biosynthesis of 15-HETE, EXC4 and LTC4 in blood eosinophils.  
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4.3 Paper III 
Basal biosynthesis of PGD2 in asthmatic subjects is increased and catalyzed by 
COX-1, whereas whole body formation of PGE2 predominantly is COX-2 
dependent (figures 13, 14 and 15). 
Urinary prostanoid metabolites in the three consecutive days of treatment with 
celecoxib or placebo were compared with the mean baseline values of the first two 
untreated days of each period. The baseline values did not differ between the periods. 
Urinary PGDM and TXM mean levels during treatment (days 3-5) were not affected by 
treatment with celecoxib.  In contrast, urinary PGEM values exhibited a profound 
inhibition which was progressive during the consecutive treatment days with celecoxib. 
The excretion of PGIM in urine was also significantly inhibited after treatment with 
celecoxib. There were higher levels of urinary PGD2 metabolites in asthmatic subjects. 
However, there were no significant differences in urinary excretion of the studied 
metabolites, PGDM, PGEM, PGIM and TXM, between the three asthmatic subgroups: 
intermittent asthma, persistent ASA/NSAID-tolerant asthma and ASA/NSAID-
intolerant asthma, neither with regard to the impact of the COX-2 inhibition nor in 
baseline levels of the measured urinary metabolites. Compared with the healthy 
controls, the asthmatic subjects displayed significantly higher basal levels of the urinary 
tetranor metabolite of PGD2, whereas the PGEM levels in urine were not significantly 
different between the groups.  
 
 
 
 
 
 
 
Figure 13. Schematic representation of the conclusions in paper III  
Showing that biosynthesis of PGD2 and TXA2 is COX-1 dependent,  
Whereas that of PGE2 and PGI2 is COX-2 dependent 
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With regard to the salivary levels of PGE2, treatment with celecoxib resulted in a 
small but significant decrease in the levels of salivary PGE2, whereas no changes were 
seen after placebo. Moreover, there were no gender differences in salivary PGE2 levels. 
Therefore, this study provides new evidence that the constitutive PGD2 
biosynthesis in asthmatics is generated predominantly by the COX-1 isoenzyme. In 
addition, the study documents elevated PGD2 metabolites which are 3-5 times higher 
than those of TXA2 and PGI2 and in a similar range as for urinary PGE2 metabolites. 
The effects of celecoxib on the urinary PGDM and PGEM did not differ between the 
healthy controls and the asthmatics. These data are in line with previous studies of the 
effects of coxibs on urinary excretion of prostanoid metabolites in healthy subjects and 
patients with cardiovascular diseases(62,68,221,222), as well as the only previous study 
with asthmatics who were given a single dose of celecoxib with subsequent 
measurements of only PGE metabolites in urine(223). Taken together, it is concluded 
that COX-1, with regard to in vivo biosynthesis of PGD2, is the quantitatively dominant 
pathway that presumably apply to the mast cells as the major or almost the exclusive 
source of PGD2 (93).  Our in vivo data thus contrast with published data in cultured 
human and murine mast cells where both COX-1 and COX-2 isoenzymes contribute to 
the biosynthesis of PGD2 (224,225).  
Although urinary excretion of PGD2 measures whole body biosynthesis, it is well 
established that the increase following challenges reflects activation of the pulmonary 
mast cells. Accordingly, the lungs are perfused well and the clearance of prostanoid 
metabolites into the bloodstream is efficient. The rate of in vivo biosynthesis of 
prostanoids at baseline is low relative to the capacity of the producing cells or tissues 
upon activation ex vivo or in vitro (226), i.e. even minor and transient increases in 
systemic availability of prostanoids is reflected by the detectable increases in excretion 
of urinary metabolites. As a result, bronchoconstrictive responses mediated by mast cell 
activation, are promptly reflected by increased urinary excretion of metabolites of 
PGD2 (87,89,227,228) and TXA2(38,229). Inhaled sodium cromoglycate, a local mast 
cell activation stabilizer in the airways, is followed by significantly decreased urinary 
excretion of PGD2 metabolites(228,230). Thus, it is likely that urinary PGDM levels do 
reflect local biosynthesis in the airways and the higher levels in asthma, observed in 
this study, provide circumstantial support for this argument. The finding of lower 
PGDM levels in healthy volunteers than in the asthmatic patients may mirror an 
increased mast cell activation even at baseline in asthma which is consistent with 
reports of increased numbers of mast cells in the smooth muscle of subjects with 
asthma(12). The effect of celecoxib in healthy controls and asthmatic subjects was 
similar suggesting that the asthmatic airway is not associated with deviations in the 
PGD2 biosynthetic pathway.The profound reduction in the biosynthesis of the 
bronchoprotective PGE2, caused by the 3-day treatment with celecoxib, was neither 
associated with any significant changes in baseline lung function nor FENO as a 
surrogate marker of airway inflammation(231).  
The finding that the well characterized AIA subjects tolerated celecoxib adds to 
previous indications(34,58,59,223) that COX-2 inhibition does not provoke 
bronchoconstriction in this particular group of patients. The study results also confirm 
previous indications that the basal levels of PGE metabolites in urine of AIA subjects 
do not differ from those in non-AIA subjects(224). The tolerance of COX-2 inhibitors 
in AIA is not explained by the inhibition of PGD2 as its biosynthesis did not alter after 
treatment with celecoxib. The study also confirmed previous data that basal levels of 
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urinary PGD2 metabolites in subjects with AIA and ATA are not different(12,38,229-
231). One of the hypothetical explanations for ASA/NSAID-intolerance is that the 
stabilization of mast cells in this particular asthmatic phenotype is dependent on the 
bronchoprotective PGE2 (161) abolishment of which in intolerance reactions leads to a 
paradoxical release of PGD2 (87). However, in this study, the profound reduction in 
levels of PGE2 metabolite, caused by celecoxib, was neither associated with 
bronchoconstriction, nor release of PGD2. 
In cultured cells from airways of AIA subjects, Harrington and colleagues have 
demonstrated that COX-1 is the functionally predominant isoform despite detectable 
but low levels of COX-2 lending support to that COX-1 catalyzes formation of the 
PGE2 in the airways and providing rationale as to why these asthmatics tolerate COX-2 
inhibitors(232). The average influence of celecoxib on PGEM was smaller in ICS-
treated asthmatics than the intermittent asthma group. This can be interpreted as to be 
consistent with the steroid-related down-regulation of COX-2(233,234), tilting 
biosynthesis in subjects maintained on ICS towards COX-1. The difference was, 
however, small, but is actually consistent with the relatively limited effects of oral 
steroid treatment on systemic PG formation in healthy subjects(235).  
Levels of PGE2 in saliva were also studied to test possible monitoring of this 
mediator in this non-invasive matrix using a routine EIA. However, only a minor 
component of the salivary PGE2 levels was accounted for by a celecoxib sensitive 
pathway. No gender differences in the salivary PGE2 levels were found, whereas an 
increased urinary excretion of PGE2 metabolites, as previously reported, were found in 
males(221,236,237). The reason for or consequence of the higher levels of urinary PGE 
metabolites in males, observed here and in previous studies, are not clear. The gender 
difference, with regard to the levels of urinary PGE, is unlikely to be due to 
biosynthesis in the prostate or other accessory genital glands of males as the 
metabolites are predominantly formed in the liver. Post-menopausal females have been 
shown to have PGE levels comparable with those in males(237) suggesting hormonal 
regulation of systemic production of PGE2. 
In this study, the findings of increased basal biosynthesis of PGD2 in asthmatics 
and the whole body biosynthesis of PGE2 being predominantly COX-2 dependent 
warrants future long-term studies to determine the clinical relevance of consequences 
of asymmetric inhibition of prostanoids, i.e. reduction of the bronchoprotective PGE2 
and maintained production of high levels of the pro-inflammatory PGD2. 
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Figure 14. Mean (SEM) urinary concentrations of (a) PGDM, (c) PGEM, (e) PGIM and (g) 
TXM during 2 untreated baseline days and on 3 consecutive days after daily intake of 
placebo (open square) or celecoxib (filled square). (b, d, f, h) Levels of the respective 
metabolite expressed as percent of baseline (dotted line in figures indicate baseline level). 
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4.4 Paper IV 
Selective COX-2 inhibition did not change allergen-induced airway obstruction or 
airway inflammation in subjects with mild atopic asthma. Short-term use of COX-
2 inhibitors is safe in asthmatics (figures 16 and 17). 
Almost two weeks of treatment with the selective COX-2 inhibitor etoricoxib 
was well tolerated with respect to a number of physiological outcomes in this study. 
Etoricoxib, a new and highly selective COX-2 inhibitor, was used for the first time in 
an allergen challenge study in a cross-over manner. The atopic asthmatic subjects did 
not display any differences neither in the pre-challenge baseline lung function nor in the 
systolic or diastolic blood pressure between the treatment and control study period.  
Following treatment with etoricoxib, the airway sensitivity to cumulatively 
increased doses of inhaled allergen was not affected with geometric mean PD20FEV1 
being 234 (range 31.7-5244) and 200 (range 12.2-3198) SQ units after drug and 
control, respectively. Neither was the immediate peak fall in FEV1 nor the decrease 
after 30 minutes different between the study arms. Methacholine responsiveness, 
expressed as PD20FEV1, was not affected by etoricoxib, the geometric mean being 229 
(range 29-4655) and 222 (range 56-2018) μg, after drug and control respectively 
The total number of cells and the percentage of eosinophils in induced sputum 
increased six hours after allergen challenge during both sessions supporting the 
allergen-induced cellular inflammatory response. The increases after inhaled allergen in 
total sputum cells and the percentage of eosinophils displayed no differences between 
the two study periods. Neither were there differences in sputum cell numbers or 
differential cell counts between baseline samples and sputum samples collected after 
etoricoxib or after the control period. Furthermore, treatment with etoricoxib did not 
give rise to any significant changes in FENO measurements within or between the two 
periods. 
Given this profile of essentially no changes after etoricoxib treatment of the primary 
physiological endpoints, it was a particular strength of the study that the biochemical 
effectiveness of the treatment was established with appropriate methods, i.e. blood 
assays of COX activities and measurements of urinary metabolites.  
Figure 15. Baseline urinary concentrations of  (a) PGDM and  (b) 
PGEM in healthy volunteers and in three groups of asthmatic 
subjects. Open diamonds indicate individual levels and horizontal 
lines indicate median value for each group 
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First, the effectiveness of COX-2 selectivity was confirmed by biochemical 
assays where measurements of thromboxane generation in clotted blood determined the 
activity of COX-1 and LPS-induced formation of PGE2 in leukocytes that of COX-2, 
respectively. After in vivo treatment with etoricoxib, the baseline PGE2 levels were 
consistently inhibited and the findings supported good adherence to the treatment by 
the study subjects.  In contrast, during the untreated period, there were no significant 
changes of the PGE2 levels in the blood. The COX-1 activity was assessed as the level 
of serum TXB2 after one hour of ex vivo clotting. There were no differences in TXB2 
levels between samples collected after etoricoxib or after no treatment.  In the 
experiments using blood from control sessions, it was documented that addition of 
etoricoxib ex vivo had no effect on TXB2 levels.  
Second, the measurement of metabolites also validated the selective effects of the 
active treatment with a major inhibition in urinary excretion of the main PGE2 
metabolite PGEM and unaffected excretion of the corresponding major tetranor 
metabolite of PGD2, PGDM.  
During the control arm of the study, there was increased excretion of tetranor-PGD2 
and 2,3-dinor TXB2 in urine during the hour following the peak drop in FEV1, 
indicating increased biosynthesis of PGD2 and TXA2. Excretion of PGD2 metabolite in 
urine increased the most and was still higher than baseline at 2 hours post peak fall in 
FEV1, whereas excretion of 2,3-dinor TXB2 had returned to basal levels during the 
second hour after the challenge. However, there was no change following the challenge 
in the urinary excretion of the PGE2 and PGI2 metabolites tetranor-PGE2 and 2,3-dinor-
6-keto-PGF1α, respectively. 
Excretion of tetranor-PGEM in urine at baseline was however significantly 
higher in males than females, whereas no gender differences were observed with 
respect to the other metabolites. Inhibition of COX-2 led to a profound reduction in the 
basal excretion of PGE2 metabolite in urine and the levels remained depressed in the 
samples collected after the challenge. Etoricoxib also caused about a 50% decrease in 
the basal urinary excretion of the PGI2 metabolite, whereas the basal and the allergen-
induced levels of urinary TXA2/PGD2 metabolites were unaffected by celecoxib.  
A consistent and significant increase in urinary excretion of LTE4 was observed 
following the allergen challenge. However, no difference in the urinary levels was 
found between the two study arms. 
In this first assessment of the impact of COX-2 inhibition on airway homeostasis 
in atopic asthmatic patients following allergen challenge, etoricoxib had no effect on 
baseline lung function, airway responsiveness to methacholine, sensitivity to allergen or 
the magnitude of the fall in FEV1 following the PD20 allergen dose. As surrogate 
markers of asthmatic airway inflammation(231,237), the FENO values and increased 
sputum eosinophils following the inhaled allergen challenge did not demonstrate any 
differences between the two study arms. 
These findings provide evidence that using COX-2 inhibitors are safe in 
asthmatics and even during mild asthmatic exacerbations. The results are also in line 
with those from paper III where we found that COX-2 contributed substantially to 
whole body PGE2 biosynthesis and that the increased basal biosynthesis of PGD2 was 
exclusively catalysed by COX-1(238). 
Substantial evidence from previous observations points towards a good 
tolerability of COX-2 inhibitors in AIA(34). The fact that the airway responses at 
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baseline and after inhaled allergen were not affected by COX-2 inhibition, suggests that 
COX-1 is the only enzyme of importance for PGD2 formation in humans.  
The atopic asthmatics in this study demonstrated signs of on-going airway 
inflammation including increased FENO, sputum eosinophils and AHR to methacholine 
suggesting minimal involvement of COX-2 pathway in PGD2 biosynthesis even under 
conditions of airway inflammation. This is consistent with the results of a bronchial 
biopsy study in seasonal allergic asthmatics, that was performed during pollen season 
and demonstrated involvement of 5-LO pathway without any increase in the expression 
of COX-2 or PGD-synthase(239). Despite the profound COX-2 related inhibition 
whole-body biosynthesis of PGE2, the PGE2 that controls the airway dynamics was not 
affected which is in line with in vitro observations demonstrating that COX-1 is 
responsible for PGE2 biosynthesis in human airway epithelium(232). Furthermore, the 
results are in agreement with the replicated studies of bronchoconstriction in AIA being 
triggered by non-selective NSAIDs, and not by COX-2 inhibitors(34,35,59). Early 
studies have suggested that NSAIDs can affect different components of the response to 
allergen-challenge in subjects with asthma(240,241). More recent studies have shown 
that non-selective COX-inhibitors have no effect on the early or late reaction to allergen 
challenge(229,242). However, the effects of selective COX-2 inhibitors on the allergen-
induced airway responses have not been investigated previously. In addition, proper 
urinary excretion of prostanoid metabolites urges a pre-treatment time of at least 3-5 
days(243). 
It is worth consideration that, in common mice models, selective COX-2 
inhibition has been reported to enhance airway responsiveness but also to inhibit airway 
inflammation. Administration of a selective COX-1 inhibitor during ovalbumin (OVA) 
challenge in mice resulted in enhanced AHR without affecting the airway inflammatory 
response, while selective COX-2 inhibition caused a reduction in the inflammatory 
cells without affecting AHR after OVA challenge(244). Peebles and 
colleagues(245,246) found that inhibition of both COX isoenzymes, COX-1 and 2, 
resulted in enhanced AHR as well as decreased PGE2 bearing in mind that both PGD2 
and PGE2 are potent relaxants of airway smooth muscle in mice(106,247,248).  In view 
of the findings in our study, the relevance of these mice models to human asthma may 
be low, at least with respect to defining the role of COX-products. 
In the control session, the allergen-induced increases in the biosynthesis of LTE4 
and TXB2 confirm the results from previous works(40,93,128,229,249). PGI2 seems to 
have a regulatory role in allergen-induced airway inflammation in humans(144,250). 
However, the urinary excretion of PGI2 metabolites was not affected during the 
untreated period.  
In conclusion, selective COX-2 inhibition in the allergen-challenge setting does 
not appear to exert any negative effects on the lung function or the inflammatory 
responses in subjects with mild atopic asthma. This provides evidence that short-term 
use of COX-2 inhibitors may be acceptable in this group of asthmatics. However, in 
more severe asthma or during heightened asthmatic airway responses, the effects may 
differ from those demonstrated in mild asthmatic subjects with stable disease. PGD2 
appears to be generated predominantly by COX-1 when the allergic airway 
inflammation is aggravated and the data also support that the bronchoprotective PGE2, 
mechanistically, is derived from COX-1. 
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3                                      3     Study day                                 Peak fall             Fall at 30 min                                     
Figure 16. Effects of etoricoxib on: a. airway sensitivity 
to allergen b. FEV1 fall (peak and 30 min after allergen)  
 
Fig. 17a. 
Fig. 17b. 
Figure 17. Effects of etoricoxib on metabolites in urine a. tetranor-PGD2  
b. tetenor-PGE2, 0 = Baseline, 1 and 2 = one hour and two hours after  
allergen challenge, respectively. 
 
Fig. 16a                       Fig. 16b 
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5. General discussion and conclusions 
The heterogeneous nature of asthma, with its different patterns of airway inflammation, 
prompts a more specific characterization of different phenotypes. Studying the role 
eicosanoids play in the asthmatic airway inflammation, under constitutive and triggered 
conditions, may offer the possibility of finding new diagnostic phenotype-specific 
biomarkers.  
In ASA/NSAID-intolerant and allergic phenotypes the asthmatic inflammation is 
characterized by involvement of mast cells and eosinophils. The clinical characteristics 
of AIA, with its salient eosinophilic inflammation and overproduction of CysLTs, make 
this clear-cut syndrome an intriguing experimental model. 
Measurement of CysLTs in different body matrices was one of the approaches 
used in this thesis to help explore a new test of capacity for in vivo CysLT release that 
would serve as a clinically applicable sensitive biomarker of AIA. A particular strength 
of the study in paper I was that AIA diagnosis was verified at the time of the study to 
avoid the known fluctuation in the clinical picture.   
In aspirin-sensitive asthmatics, the higher basal levels of LTE4 in the three body 
matrices (induced sputum, ex vivo stimulated blood and saliva), compared with those in 
aspirin-tolerant asthmatics, provides further support to the selective overproduction of 
CysLTs which has been suggested to be due to increased expression of LTC4 synthase 
in eosinophils in this distinct phenotype. However, when sputum CysLT levels were 
expressed per million eosinophils, the levels were not greater in the AIA group 
suggesting that the increased baseline levels of CysLTs in AIA may be due to increased 
numbers of eosinophils rather than an overactivation of each eosinophil(37,251). This 
study has for the first time shown higher baseline levels of salivary CysLTs in aspirin-
sensitive asthmatics than subjects with aspirin-tolerant asthma. However, there was no 
increase in salivary CysLTs after either bronchial challenges suggesting that salivary 
levels of CysLTs are unlikely to reflect direct overflow from the circulation. 
Measurement of CysLTs in saliva appears to introduce an advantage over that in other 
body matrices with regard to the non-invasive nature of saliva and that it offers a direct 
assessment of in vivo concentrations of LTs. However, it has to be addressed that 
methods of collecting and processing saliva have to be optimized. The influence of 
diurnal variation and the lack of a dilution factor are issues that also should be 
considered. Furthermore, it is important to determine the sources of leukotrienes in 
saliva, e.g. factors related to the cells in the oral cavity. The observation that basal 
CysLT levels are raised in ex vivo stimulated whole blood from subjects with AIA is 
also new. However, the method is time-consuming with the need of an immediate 
incubation of the cells. Measurement of CysLTs in asthmatic subjects is important from 
the diagnostic and therapeutic point of view as the biosynthesis of leukotrienes is not 
affected by treatment with corticosteroids despite their widespread anti-inflammatory 
action(252,253)(132). 
In an exploratory experiment, highly purified eosinophils in subjects with AIA 
revealed the capacity to release the 15-LO product, EXC4, which was higher when the 
cellular ex vivo responsiveness to COX inhibition was tested through incubation with 
ASA.  
The similarity between the aspirin-sensitive and severe asthmatics, with regard to 
the effect of ASA on release of arachidonic acid-induced 15-LO products (EXC4 and 
15-HETE) and ionophore-induced 5-LO product (LTC4), indicates that aspirin 
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hypersensitivity is unlikely to be involved in the underlying mechanism.  The most 
likely explanation is therefore that the COX inhibition abolished PGE2 known to exert 
an important negative regulatory role on mediator release in inflammatory cells in 
general. In addition to the known eosinophilia in AIA and SA groups, another 
contributing factor to the remarkable degree of 15-LO activity would be increased 
numbers of hyperactive hypodense eosinophils. These findings indicate that the 
capacity of eosinophils to produce 15-LO products could be used as a biomarker for 
asthma severity. The possible involvement of 15-HETE in aspirin-sensitive and severe 
asthma suggests that therapies targeting the 15-LO pathway might be of value in 
treatment of these two asthma phenotypes. However, further exploration of the 
biological role of lipid mediators synthesized via 15-LO are required. Some metabolites 
such as lipoxin A4 have even been suggested to be protective factors(254) which would 
prompt for agonist intervention. 
In this thesis, pharmacological interventions using selective COX-2 inhibitors 
were performed to evaluate the role of COX-1 and COX-2 iso-enzymes in the 
biosynthesis of the bronchoconstrictive/proinflammatory PGD2 and the 
bronchoprotective PGE2 in asthmatic subjects under basal and triggered conditions. 
The basal biosynthesis of PGD2 was maintained during three days of treatment 
with celecoxib indicating that formation of this pro-inflammatory prostaglandin is 
catalyzed by COX-1. In contrast, COX-2-inhbition caused a profound inhibition of 
biosynthesis of PGE2 indicating that whole body biosynthesis of PGE2 is predominantly 
COX-2 dependent. Thus, COX-1 was shown to be the quantitatively dominant pathway 
for in vivo biosynthesis of PGD2, and this would presumably apply to the mast cell that 
is thought to be the major source of PGD2 in humans. Subjects with asthma were 
shown to have higher basal biosynthesis of PGD2 without any difference between the 
asthmatic phenotypes. 
The unaltered biosynthesis of PGD2 after celecoxib indicates that the tolerance of 
COX-2 inhibitors in AIA is not explained by inhibition of PGD2. The paradoxical 
increased release of PGD2 during the intolerance reaction(87) is thought to be attributed 
to mast cell activation occurring as a result of removal of protective PGE2.  
Close to two weeks of treatment with the selective COX-2 inhibitor etoricoxib was well 
tolerated with respect to a number of physiological outcomes in this study. The 
traditional method of measuring PD20 to allergen was applied because this a reliable 
index of sensitivity to allergen. Etoricoxib is a new and highly selective COX-2 
inhibitor and this strategy was considered suitable for the first time use in an allergen 
challenge setting. 
This first investigation of the impact of COX-2 inhibition on airway homeostasis in 
atopic asthmatic patients following allergen challenge demonstrated no significant 
effects on the baseline lung function, AHR to methacholine, sensitivity to allergen or 
the magnitude of FEV1 fall for the PD20 allergen dose. Furthermore, the surrogate 
marker of airway inflammation, exhaled nitric oxide, and the allergen-induced increase 
in sputum eosinophils displayed no significant differences in comparison with the 
untreated study arm. These results support the notion that short-term use of a coxib is 
safe in asthmatics, even during a mild asthma attack. 
A particular strength of the study was that the blood assays for COX-1 and COX-2 
inhibition confirmed that the study participants had complied with the treatment and 
that only COX-2 activity, measured as LPS-induced PGE2 formation, was inhibited. In 
addition, there was a profound inhibition of PGEM excretion in urine, whereas urinary 
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PGDM was unaffected. These results demonstrate that COX-1 by far is the most 
important enzyme for PGD2 formation in humans. Our data also suggest that the PGE2 
which controls airway dynamics is not affected by systemic COX-2 inhibition, despite 
the pronounced involvement of COX-2 in whole-body PGE2 formation. This finding is 
consistent with in vitro observations demonstrating that COX-1 is responsible for PGE2 
biosynthesis in human airway epithelium(232). These results warrant future studies 
with selective receptor antagonists or selective inhibitors of distal class-specific 
isomerases (e.g. PGD-synthases or PGE-synthases) to define the role of individual 
prostaglandins in allergen evoked reactions. 
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